<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antiviral treatment for Bell's palsy (idiopathic facial paralysis) - Gagyor, I - 2019 | Cochrane Library</title> <meta content="Antiviral treatment for Bell's palsy (idiopathic facial paralysis) - Gagyor, I - 2019 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001869.pub9/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antiviral treatment for Bell's palsy (idiopathic facial paralysis) - Gagyor, I - 2019 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001869.pub9/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001869.pub9" name="dc.identifier" scheme="DOI"/> <meta content="Antiviral treatment for Bell's palsy (idiopathic facial paralysis)" name="citation_title"/> <meta content="Ildiko Gagyor" name="citation_author"/> <meta content="Universitätsklinikum Würzburg" name="citation_author_institution"/> <meta content="Gagyor_I@ukw.de" name="citation_author_email"/> <meta content="Vishnu B Madhok" name="citation_author"/> <meta content="Park House Surgery" name="citation_author_institution"/> <meta content="Fergus Daly" name="citation_author"/> <meta content="Frontier Science (Scotland) Ltd" name="citation_author_institution"/> <meta content="Frank Sullivan" name="citation_author"/> <meta content="University of St Andrews" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD001869.pub9" name="citation_doi"/> <meta content="2019" name="citation_date"/> <meta content="2019/09/05" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001869.pub9/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001869.pub9/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001869.pub9/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Inflammatory Agents [*therapeutic use]; Antiviral Agents [*therapeutic use]; Bell Palsy [*drug therapy, virology]; Drug Therapy, Combination; Randomized Controlled Trials as Topic; Treatment Outcome" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001869.pub9&amp;doi=10.1002/14651858.CD001869.pub9&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="STpJR8yz";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001869\x2epub9\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001869\x2epub9\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","fr","pl","hr","fa","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001869.pub9",title:"Antiviral treatment for Bell\u0027s palsy (idiopathic facial paralysis)",firstPublishedDate:"Sep 5, 2019 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Neuromuscular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001869.pub9&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001869.pub9';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001869.pub9/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001869.pub9/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001869.pub9%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001869.PUB9" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001869.pub9/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001869.PUB9" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001869.pub9/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001869.pub9/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>20607 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001869.pub9" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-sec-0110"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-sec-0043"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-sec-0067"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-sec-0104"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/appendices#CD001869-sec-0115"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/table_n/CD001869StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/table_n/CD001869StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> <li aria-label="There has been an important change to the conclusions of the review." class="status-item up-to-date custom-tooltip" data-status="conclusionchanged" title="There has been an important change to the conclusions of the review."> <a class="btn secondary" href="information#history">Conclusions changed</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antiviral treatment for Bell's palsy (idiopathic facial paralysis)</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information#CD001869-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Ildiko Gagyor</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information#CD001869-cr-0003">Vishnu B Madhok</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information#CD001869-cr-0004">Fergus Daly</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information#CD001869-cr-0005">Frank Sullivan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information/en#CD001869-sec-0126">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 05 September 2019 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001869.pub9">https://doi.org/10.1002/14651858.CD001869.pub9</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001869-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001869-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001869-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001869-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001869-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001869-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001869-abs-0001" lang="en"> <section id="CD001869-sec-0001"> <h3 class="title" id="CD001869-sec-0001">Background</h3> <p>Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. This review was first published in 2001 and most recently updated in 2015. Since a significant benefit of corticosteroids for the early management of Bell's palsy has been demonstrated, the main focus of this update, as in the previous version, was to determine the effect of adding antivirals to corticosteroid treatment. We undertook this update to integrate additional evidence and to better assess the robustness of findings, taking risk of bias fully into account. </p> </section> <section id="CD001869-sec-0002"> <h3 class="title" id="CD001869-sec-0002">Objectives</h3> <p>To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy. </p> </section> <section id="CD001869-sec-0003"> <h3 class="title" id="CD001869-sec-0003">Search methods</h3> <p>We searched the Cochrane Neuromuscular Specialised Register, CENTRAL, MEDLINE, Embase, and LILACS in July 2019. We reviewed the bibliographies of the identified trials and contacted trial authors to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies. </p> </section> <section id="CD001869-sec-0004"> <h3 class="title" id="CD001869-sec-0004">Selection criteria</h3> <p>We considered randomised controlled trials (RCTs) or quasi‐RCTs of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that followed‐up participants for less than three months. </p> </section> <section id="CD001869-sec-0005"> <h3 class="title" id="CD001869-sec-0005">Data collection and analysis</h3> <p>We independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures. We performed sensitivity analyses excluding trials at high or unclear risk of bias in at least five domains, and reported these data as the primary analyses. </p> </section> <section id="CD001869-sec-0006"> <h3 class="title" id="CD001869-sec-0006">Main results</h3> <p>Fourteen trials, including 2488 participants, met the inclusion criteria. Most were small, and most were at high or unclear risk of bias in multiple domains. We included four new studies at this update. </p> <p><b>Incomplete recovery</b> </p> <p>A combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in people with Bell's palsy compared to corticosteroids alone (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.38 to 1.74; 3 trials, N = 766; random‐effects; low‐certainty evidence). We excluded 10 trials that were at high or unclear risk of bias in several domains from this analysis and limited all analyses to studies at lower risk of bias. Recovery rates were better in participants receiving corticosteroids alone than antivirals alone (RR 2.69, 95% CI 0.73 to 10.01; 2 trials, N = 667; random‐effects), but the result was imprecise and allowed for the possibility of no effect. The rate of incomplete recovery was lower with antivirals plus corticosteroids than with placebo or no treatment (RR 0.56, 95% CI 0.42 to 0.76; 2 trials, N = 658; random‐effects). Antivirals alone had no clear effect on incomplete recovery rates compared with placebo, but the result was imprecise (RR 1.10, 95% CI 0.87 to 1.40; 2 trials, N = 658; fixed‐effect). For people with severe Bell's palsy (House‐Brackmann score of 5 and 6, or equivalent on other scales), we found that the combination of antivirals and corticosteroids had no clear effect on incomplete recovery at month six compared to corticosteroids alone, although the result was again imprecise (RR 0.82, 95% CI 0.57 to 1.17; 2 trials, N = 98; random‐effects). </p> <p><b>Motor synkinesis or crocodile tears</b> </p> <p>Antivirals plus corticosteroids reduced the proportion of participants who experienced these long‐term sequelae from Bell's palsy compared to placebo plus corticosteroids (RR 0.56, 95% CI 0.36 to 0.87; 2 trials, N = 469; fixed‐effect; moderate‐certainty evidence). Antivirals plus corticosteroids reduced long‐term sequelae compared to placebo but there was no clear difference in this outcome with antivirals alone compared to placebo. </p> <p><b>Adverse events</b> </p> <p>Adverse event data were available in four studies providing data on 1592 participants. None of the four comparisons showed clear differences in adverse events between treatment and comparison arms (very low‐certainty evidence); for the comparison of antivirals plus corticosteroids and corticosteroids alone in studies at lower risk of bias, the RR was 1.17 (95% CI 0.81 to 1.69; 2 trials, N = 656; fixed‐effect; very low‐certainty evidence). </p> </section> <section id="CD001869-sec-0007"> <h3 class="title" id="CD001869-sec-0007">Authors' conclusions</h3> <p>The combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in comparison to corticosteroids alone in Bell's palsy of various degrees of severity, or in people with severe Bell's palsy, but the results were very imprecise. Corticosteroids alone were probably more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no clear benefit from antivirals alone over placebo. </p> <p>The combination of antivirals and corticosteroids probably reduced the late sequelae of Bell's palsy compared with corticosteroids alone. Studies also showed fewer episodes of long‐term sequelae in corticosteroid‐treated participants than antiviral‐treated participants. </p> <p>We found no clear difference in adverse events from the use of antivirals compared with either placebo or corticosteroids, but the evidence is too uncertain for us to draw conclusions. </p> <p>An adequately powered RCT in people with Bell’s palsy that compares different antiviral agents may be indicated. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001869-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001869-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001869-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001869-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001869-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD001869-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD001869-abs-0015">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001869-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD001869-abs-0010">Polski</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001869-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD001869-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001869-abs-0005" lang="en"> <h3>Antiviral treatment for Bell's palsy</h3> <p><b>Review question</b> </p> <p>We reviewed the evidence about the effect of antiviral therapy (drugs used specifically to treat viral infections), alone or in combination with any other therapy, on Bell's palsy. Our focus in this updated review was combined therapy with antiviral drugs and corticosteroids (which are drugs used to reduce inflammation) as there is already good evidence that corticosteroids can reduce rates of incomplete recovery from Bell's palsy. </p> <p><b>Background</b> </p> <p>Bell's palsy is a disease of the facial nerve that causes one side of the face to be paralysed. Some studies have suggested that it is caused by the same viral infections that cause cold sores or shingles and investigated the effect of antiviral therapy. Earlier versions of this review have found that antivirals alone are not helpful compared to a dummy pill, and are less effective than corticosteroids alone. However, studies of antiviral treatment in combination with corticosteroids have conflicting results. </p> <p><b>Study characteristics</b> </p> <p>We identified 14 trials, which included 2488 participants with mild, moderate, or severe one‐sided Bell's palsy of unknown cause. Participants were aged from 14 to 84 years. The trials compared:<br/> ‐ antivirals plus corticosteroids to corticosteroids alone or in combination with placebo;<br/> ‐ antivirals alone or in combination with placebo to placebo or no treatment;<br/> ‐ antivirals alone or in combination with placebo to corticosteroid treatment alone or in combination with placebo; or<br/> ‐ antivirals plus corticosteroids to placebo or no treatment. </p> <p>For the majority of the studies, no information on funding was given. The remaining were mostly partly public funded, and one trial was funded by a pharmaceutical company. </p> <p>Eleven studies had high or uncertain risk of bias from various factors that can systematically affect trial results. We chose to base our conclusions only on data from three studies at a lower risk of bias. </p> <p><b>Key results and certainty of the evidence</b> </p> <p>The review showed that there may be no clear difference in rates of incomplete recovery from Bell's palsy after treatment with the combination of antivirals and corticosteroids, compared to corticosteroids alone. This finding was of low certainty and was based on data from three trials involving 766 people with Bell's palsy of various degrees of severity. We excluded data from 10 trials with multiple potential sources of bias. However, we can be moderately confident that the combined therapy reduced the number of people left with long‐term effects of Bell's palsy (excessive tearing of the eyes or an abnormal facial movement) compared to corticosteroid treatment alone. </p> <p>Data from two studies (98 participants) showed that in people with severe Bell's palsy (complete or almost complete facial paralysis), combined antivirals and corticosteroids had no clear effect on recovery compared with corticosteroid treatment alone. </p> <p>Corticosteroids alone were more effective than antivirals alone on rates of incomplete recovery (667 participants, 2 trials); antivirals and corticosteroids combined were more effective than placebo or no treatment (658 participants, 2 trials); and there was no clear benefit from antivirals alone over placebo (658 participants, 2 trials). </p> <p>Although, based on data from two trials (656 participants), we found no clear difference in the occurrence of side effects between people receiving both antivirals and corticosteroids, compared to those receiving corticosteroids alone, this evidence is too uncertain for us to draw conclusions. </p> <p>Large studies in people with Bell's palsy comparing additional antiviral agents may be indicated in the future. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001869-sec-0110" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001869-sec-0110">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001869-sec-0172">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001869-sec-0110"></div> <h3 class="title" id="CD001869-sec-0111">Implications for practice</h3> <section id="CD001869-sec-0111"> <p>Among participants with Bell's palsy of various degrees of severity, combination therapy with antivirals and corticosteroids may have little or no effect on rates of incomplete recovery in comparison to corticosteroids alone, and there may be no clear difference with the combination therapy compared to corticosteroids alone among people with severe Bell's palsy. </p> <p>Corticosteroids alone were probably more effective than antivirals alone with regard to recovery rates, and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no clear benefit from antivirals alone over placebo. </p> <p>The combination of antivirals and corticosteroids probably reduce the late sequelae of Bell's palsy compared with corticosteroids alone. The studies also showed fewer episodes of long‐term sequelae in corticosteroid‐treated participants compared with antiviral‐treated participants. </p> <p>We found no clear difference in adverse events from the use of antivirals compared with either placebo or corticosteroids, but the evidence was too uncertain for us to draw conclusions. </p> </section> <h3 class="title" id="CD001869-sec-0112">Implications for research</h3> <section id="CD001869-sec-0112"> <p>When we excluded small trials at high risk of bias from our analyses, we did not find convincing evidence of an improvement in rates of incomplete recovery in people with severe Bell's palsy following combined treatment with antivirals and corticosteroids, compared to corticosteroids alone. Although this evidence came from less than one‐third of the trials, they were those at low risk of bias, and the evidence, while still of low certainty, may be more reliable than the complete data set. A further large independent, well‐conducted study might help replicate and confirm these findings. Additional work in this area could address the question of the best treatment for mild to moderate and severe Bell's palsy raised by the possible causes of heterogeneity in most of the comparisons in this review. Depending upon the results of this analysis, an adequately powered randomised controlled trial (RCT) in people with Bell’s palsy comparing additional antiviral agents or immune modulators may be indicated. </p> <p>More work is needed to assess the likelihood of long‐term cosmetic sequelae, which should be reported in all future trials. There is no further need to conduct trials with a placebo group on this topic, as a clear benefit from corticosteroid therapy is evident. Moreover, in future studies, antivirals should be tested in combination with corticosteroids and not alone if an antiviral effect is expected. Future studies should be done to assess the impact of the variables, such as time from diagnosis until treatment, severity of palsy at baseline, and age of participants at presentation on outcomes. Work assessing a wider range of endpoints, such as quality of life and perceived disability, should be undertaken with the goal of developing a better understanding of Bell's palsy for the affected person. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001869-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001869-sec-0036"></div> <div class="table" id="CD001869-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment (AS versus OS) for Bell's palsy (idiopathic facial paralysis)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment (AS versus OS) for Bell's palsy (idiopathic facial paralysis)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Bell's palsy (idiopathic facial paralysis)<br/> <b>Setting:</b> primary, secondary and tertiary care<br/> <b>Intervention:</b> antivirals plus corticosteroids (AS)<br/> <b>Comparison:</b> corticosteroids plus placebo or no treatment (OS) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids plus placebo or no treatment (OS)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Antivirals plus corticosteroids (AS)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference with AS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incomplete recovery at end of study<br/> № of participants: 766<br/> (3 RCTs) </p> <p>Follow‐up: 3 to 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.38 to 1.74) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be little or no difference between AS and OS in the proportion of participants with incomplete recovery at the end of the studies. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 per 1000 (65 to 300)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/> (107 fewer to 128 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Motor synkinesis or crocodile tears<br/> № of participants: 469<br/> (2 RCTs) </p> <p>Follow‐up: 3 to 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.36 to 0.87) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AS probably reduces the proportion of participants with motor synkinesis or crocodile tears at 3 to 12 months compared to OS. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 per 1000 (70 to 169)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 fewer per 1000 (124 fewer to 25 fewer per 1000)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> № of participants: 656<br/> (2 RCTs) </p> <p>Follow‐up: 3 to 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR<br/> 1.17 (0.81 to 1.68) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether the number of people who experience adverse events is different with AS than OS. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (110 to 229)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 more per 1000 (26 fewer to 93 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AS</b> : antivirals plus corticosteroids; <b>CI:</b> confidence interval; <b>OS</b> : corticosteroids plus placebo or no treatment; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the certainty of evidence once due to differing results of the included studies (inconsistency). As our primary analysis we reported the results of a sensitivity analysis excluding 10 of 13 trials which were at high or unclear risk of bias in several domains. The effect estimate from the full data set was RR 0.54, 95% CI 0.38 to 0.77; 13 trials, N = 1729 , but there were very serious study limitations in the full data set, in addition to heterogeneity.<br/> <sup>b</sup>We downgraded the certainty of the body of evidence once because the RR had wide CIs that included the possibility of a very little effect and a large effect (imprecision).<br/> <sup>c</sup>We downgraded the certainty of evidence for this outcome for publication bias, as only two studies in this comparison reported this outcome.<br/> <sup>d</sup>We downgraded the certainty of the body of evidence for this outcome once for publication bias as only 4 of the 13 studies reported adverse events.<br/> <sup>e</sup>We downgraded the certainty of the body of evidence twice for imprecision as the CIs were wide and encompassed the possibility of an effect in either direction. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001869-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001869-sec-0037">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001869-sec-0136">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD001869-sec-0037"></div> <section id="CD001869-sec-0038"> <h3 class="title" id="CD001869-sec-0038">Description of the condition</h3> <p>Bell's palsy is an acute, generally unilateral paralysis or weakness of facial musculature consistent with peripheral facial nerve dysfunction, of no detectable cause (<a href="./references#CD001869-bbs2-0064" title="NiparkoJK , MattoxDE . Bell's palsy and herpes zoster oticus. In: JohnsonRT , GriffinJW editor(s). Current Therapy in Neurologic Disease. 4th Edition. St Louis, Missouri: BC Decker, 1993:355‐61. [ISBN: 0801677300] ">Niparko 1993</a>). Additional symptoms frequently include pain around or behind the ear on the affected side, sometimes extending into the occipital or cervical regions. Impaired tolerance to ordinary levels of noise and disturbed sense of taste on the affected side may also be present (<a href="./references#CD001869-bbs2-0041" title="BurgessLP , YimDW , LeporeML . Bell's palsy: the steroid controversy revisited. Laryngoscope1984;94(11 Pt 1):1472‐6. [PUBMED: 6387352 ] ">Burgess 1984</a>). </p> <p>Epidemiological studies have reported an annual incidence of 23 to 25 per 100,000 per year, but a recent study using a general practice database suggests it may be even higher, at 37 per 100,000 per year (<a href="./references#CD001869-bbs2-0072" title="VictorM , MartinJ . Disorders of the cranial nerves. In: IsselbacherKJ editor(s). Harrison's Principles of Internal Medicine. 13th Edition. New York: McGraw‐Hill, 1994:2347‐52. [ISBN: 0070323704] ">Victor 1994</a>;<a href="./references#CD001869-bbs2-0059" title="MartynCN , HughesRA . Epidemiology of peripheral neuropathy. Journal of Neurology, Neurosurgery &amp; Psychiatry1997;62(4):310‐8. [PUBMED: 9120441] ">Martyn 1997</a>;<a href="./references#CD001869-bbs2-0061" title="MoralesDR , DonnanPT , DalyF , StaaTV , SullivanFM . Impact of clinical trial findings on Bell's palsy management in general practice in the UK 2001‐2012: interrupted time series regression analysis. BMJ Open2013;3(7):e003121. [PUBMED: 23864211] ">Morales 2013</a>). The condition affects men and women more or less equally, and was once thought to be most common in the 30‐ to 45‐year age group (<a href="./references#CD001869-bbs2-0066" title="PeitersenE . The natural history of Bell's Palsy. American Journal of Otology1982;4(2):107‐11. [PUBMED: 7148998 ] ">Peitersen 1982</a>;<a href="./references#CD001869-bbs2-0055" title="KatusicSK , BeardCM , WiederholtWC , BergstralhEJ , KurlandLT . Incidence, clinical features and prognosis in Bell's Palsy, Rochester, Minnesota, 1968‐1982. Annals of Neurology1986;20(5):622‐7. [PUBMED: 3789675] ">Katusic 1986</a>;<a href="./references#CD001869-bbs2-0075" title="YanagiharaN , YumotoE , ShibaharaT . Familial Bell's palsy: analysis of 25 families. Annals of Otology, Rhinology and Laryngology Supplement1988;137:8‐10. [PUBMED: 3144233] ">Yanagihara 1988</a>;<a href="./references#CD001869-bbs2-0038" title="BatemanDE . Facial palsy. British Journal of Hospital Medicine1992;47(6):430‐1. [PUBMED: 1568084] ">Bateman 1992</a>;<a href="./references#CD001869-bbs2-0040" title="BrandenbergNA , AnnegersJF . Incidence and risk factors for Bell's Palsy in Laredo, Texas: 1974‐1982. Neuroepidemiology1993;12(6):313‐25. [PUBMED: 8309506] ">Brandenberg 1993</a>;<a href="./references#CD001869-bbs2-0067" title="PeitersenE . Bell's palsy: the spontaneous course of 2,500 peripheral facial nerve palsies of different etiologies. Acta Oto‐Laryngologica2002;122(Suppl 549):4‐30. [PUBMED: 12482166 ] ">Peitersen 2002</a>). However, a recent primary care database study suggests a second peak in the over‐70s (<a href="./references#CD001869-bbs2-0061" title="MoralesDR , DonnanPT , DalyF , StaaTV , SullivanFM . Impact of clinical trial findings on Bell's palsy management in general practice in the UK 2001‐2012: interrupted time series regression analysis. BMJ Open2013;3(7):e003121. [PUBMED: 23864211] ">Morales 2013</a>). Bell's palsy presents disproportionately amongst pregnant women and people who have diabetes, influenza, a cold, or some other upper respiratory ailment. On average, a British general practitioner will see one person who has developed the condition every 12 to 18 months. Both sides of the face are affected equally often (<a href="./references#CD001869-bbs2-0068" title="PrescottCA . Idiopathic facial nerve palsy (the effect of treatment with steroids). Journal of Laryngology and Otology1988;102(5):403‐7. [PUBMED: 3397632 ] ">Prescott 1988</a>). </p> <p>The aetiology of Bell's palsy is still debated. A viral infection, vascular ischaemia, autoimmune inflammatory disorders, and heredity have been proposed as underlying causes (<a href="./references#CD001869-bbs2-0036" title="AdourKK . Current concepts in neurology: diagnosis and management of facial paralysis. New England Journal of Medicine1982;307(6):348‐51. [PUBMED: 7088100] ">Adour 1982</a>;<a href="./references#CD001869-bbs2-0041" title="BurgessLP , YimDW , LeporeML . Bell's palsy: the steroid controversy revisited. Laryngoscope1984;94(11 Pt 1):1472‐6. [PUBMED: 6387352 ] ">Burgess 1984</a>;<a href="./references#CD001869-bbs2-0057" title="LorberB . Are all diseases infectious?. Annals of Internal Medicine1996;125(10):844‐51. [PUBMED: 8928993] ">Lorber 1996</a>;<a href="./references#CD001869-bbs2-0056" title="LacknerA , KesslerHH , WalchC , QuasthoffS , RaggamRB . Early and reliable detection of herpes simplex virus type 1 and varicella zoster virus DNAs in oral fluid of patients with idiopathic peripheral facial nerve palsy: Decision support regarding antiviral treatment?. Journal of Medical Virology2010;82(9):1582‐5. [PUBMED: 20648613] ">Lackner 2010</a>). A viral aetiology has gained popularity since the isolation of herpes simplex virus type 1 genome from the saliva and facial nerve endoneurial fluid of people with this condition (<a href="./references#CD001869-bbs2-0062" title="MurakamiS , MizobuchiM , NakashiroY , DoiT , HatoN , YanagiharaN . Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Annals of Internal Medicine1996;124(1 Pt 1):27‐30. [PUBMED: 7503474] ">Murakami 1996</a>;<a href="./references#CD001869-bbs2-0056" title="LacknerA , KesslerHH , WalchC , QuasthoffS , RaggamRB . Early and reliable detection of herpes simplex virus type 1 and varicella zoster virus DNAs in oral fluid of patients with idiopathic peripheral facial nerve palsy: Decision support regarding antiviral treatment?. Journal of Medical Virology2010;82(9):1582‐5. [PUBMED: 20648613] ">Lackner 2010</a>). On the whole, the prognosis is favourable, though a significant proportion of people who are left untreated have residual symptoms. One of the largest series of people with Bell's palsy, which included people receiving no treatment, showed that 85% of people began to recover within three weeks after onset (<a href="./references#CD001869-bbs2-0066" title="PeitersenE . The natural history of Bell's Palsy. American Journal of Otology1982;4(2):107‐11. [PUBMED: 7148998 ] ">Peitersen 1982</a>). Partial recovery usually occurred within three to six months for the remaining 15%. The same series showed that normal facial expression reappeared in 71% of cases, 13% had insignificant sequelae (long‐term after effects), and the final 16% had permanently diminished function with aberrant innervation (expressed as motor synkinesis or autonomic dysfunction), and postparalytic spasms. </p> </section> <section id="CD001869-sec-0039"> <h3 class="title" id="CD001869-sec-0039">Description of the intervention</h3> <p>The treatment of Bell's palsy was highly controversial until 2008, at which time corticosteroids alone were shown to be effective in treating the condition (<a href="./references#CD001869-bbs2-0058" title="MadhokVB , GagyorI , DalyF , SomasundaraD , SullivanM , GammieF , et al. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD001942.pub5] ">Madhok 2016</a>). Previous Cochrane Reviews on the treatment of Bell's palsy examined the effectiveness of oral prednisolone and aciclovir or valaciclovir (<a href="./references#CD001869-bbs2-0077" title="AllenD , DunnL . Aciclovir or valaciclovir for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD001869.pub2; PUBMED: 15266457 ] ">Allen 2004</a>; <a href="./references#CD001869-bbs2-0081" title="LockhartP , DalyF , PitkethlyM , ComerfordN , SullivanF . Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD001869.pub4; PUBMED: 19821283] ">Lockhart 2009</a>; <a href="./references#CD001869-bbs2-0080" title="GagyorI , MadhokVB , DalyF , SomasundaraD , SullivanM , GammieF , et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD001869.pub8; PUBMED: 26559436 ] ">Gagyor 2015c</a>). Several studies excluded from the analysis in these reviews either failed to randomise participants or, when correctly randomised, results were erroneously interpreted in a favourable light (<a href="./references#CD001869-bbs2-0060" title="MayM , WetteR , HardinWBJr , SullivanJ . The use of steroids in Bell's palsy: a prospective controlled study. Laryngoscope1976;86(8):1111‐22. [PUBMED: 781439] ">May 1976</a>;<a href="./references#CD001869-bbs2-0073" title="WolfSM , WagnerJH , DavidsonS , ForsytheA . Treatment of Bell's palsy with prednisone: a prospective randomized study. Neurology1978;28(2):158‐61. [PUBMED: 340980] ">Wolf 1978</a>). High‐dose corticosteroid therapy has several potential side effects, including peptic ulceration, hypertension, and confusional states. Antiviral therapy was considered expensive, and treatment was reserved for circumstances in which a clear benefit appeared likely. Previous recommendations suggested that antivirals needed to be started within 48 hours, although a study of viral replication in participants with Bell's palsy suggests that the window might be extended (<a href="./references#CD001869-bbs2-0033" title="AbikoY , IkedaM , HondoR . Secretion and dynamics of herpes simplex virus in tears and saliva of patients with Bell's Palsy. Otology &amp; Neurotology2002;23(5):779‐83. [PUBMED: 12218634] ">Abiko 2002</a>). </p> </section> <section id="CD001869-sec-0040"> <h3 class="title" id="CD001869-sec-0040">How the intervention might work</h3> <p>Bell's palsy is associated with an inflammation of the facial nerve. Since herpes simplex virus has been detected in cerebrospinal fluid of affected patients, antiviral treatment was tested in trials aiming to eradicate the virus (<a href="./references#CD001869-bbs2-0062" title="MurakamiS , MizobuchiM , NakashiroY , DoiT , HatoN , YanagiharaN . Bell palsy and herpes simplex virus: identification of viral DNA in endoneurial fluid and muscle. Annals of Internal Medicine1996;124(1 Pt 1):27‐30. [PUBMED: 7503474] ">Murakami 1996</a>). </p> </section> <section id="CD001869-sec-0041"> <h3 class="title" id="CD001869-sec-0041">Why it is important to do this review</h3> <p>Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. The 2009 update of this Cochrane Review included large‐scale randomised controlled trials (RCTs) of antivirals and corticosteroids that had been published in the years before the review. The authors stated that, compared to placebo, antivirals did not contribute to a significant improvement in the rate or extent of recovery of trial participants (<a href="./references#CD001869-bbs2-0081" title="LockhartP , DalyF , PitkethlyM , ComerfordN , SullivanF . Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD001869.pub4; PUBMED: 19821283] ">Lockhart 2009</a>), but that when added to corticosteroids, the rate of recovery was slightly better than corticosteroids alone or corticosteroids with placebo. This result was confirmed in the last update which included three additional trials (<a href="./references#CD001869-bbs2-0080" title="GagyorI , MadhokVB , DalyF , SomasundaraD , SullivanM , GammieF , et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD001869.pub8; PUBMED: 26559436 ] ">Gagyor 2015c</a>). The review authors requested withdrawal of an update of the review published earlier that year (<a href="./references#CD001869-bbs2-0079" title="GagyorI , MadhokVB , DalyF , SomasundaraD , SullivanM , GammieF , et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2015, Issue 7. [DOI: 10.1002/14651858.CD001869.pub6; PUBMED: 26130372] ">Gagyor 2015b</a>), as it also included a fourth trial (<a href="https://archie.cochrane.org/sections/documents/view?version=z1506161411540953244104488116595%26format=REVMAN#STD-Abdelghany-2013" target="_blank">Abdelghany 2013</a>), which has since been withdrawn. We requested withdrawal of that version of the review and republished our analyses. </p> <p>Since a significant benefit of corticosteroids for the early management of Bell's palsy has been previously demonstrated (<a href="./references#CD001869-bbs2-0081" title="LockhartP , DalyF , PitkethlyM , ComerfordN , SullivanF . Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2009, Issue 4. [DOI: 10.1002/14651858.CD001869.pub4; PUBMED: 19821283] ">Lockhart 2009</a>; <a href="./references#CD001869-bbs2-0058" title="MadhokVB , GagyorI , DalyF , SomasundaraD , SullivanM , GammieF , et al. Corticosteroids for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2016, Issue 7. [DOI: 10.1002/14651858.CD001942.pub5] ">Madhok 2016</a>), the main focus of this update, as in the previous version, was to determine the effect of the combination of antivirals and corticosteroids versus corticosteroids alone or in combination with placebo. The current review updates these findings with additional studies and involves a reanalysis of the results using sensitivity analyses, excluding studies at high or unclear risk of bias in at least five categories. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001869-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001869-sec-0042">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001869-sec-0141">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001869-sec-0042"></div> <p>To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001869-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001869-sec-0043">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001869-sec-0142">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001869-sec-0043"></div> <section id="CD001869-sec-0044"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001869-sec-0045"> <h4 class="title">Types of studies</h4> <p>We searched for all randomised controlled trials (RCTs) or quasi‐RCTs (which are trials that employ alternate or other systematic allocation) involving an antiviral (aciclovir, valaciclovir, or famciclovir) alone or in combination with any other therapy in the treatment of Bell's palsy, reported in any language. The duration of studies included in this review ranges from three to 12 months; the minimum study duration was three months. Unlike the previous version of the review we did not exclude studies at high risk of bias, but conducted sensitivity analyses to determine their effect on the outcome. Studies were eligible for the review regardless of publication status. </p> </section> <section id="CD001869-sec-0046"> <h4 class="title">Types of participants</h4> <p>We considered all trials where participants had a diagnosis of unilateral facial paralysis of unknown cause and satisfied the trial authors' requirements for eligibility and inclusion. </p> </section> <section id="CD001869-sec-0047"> <h4 class="title">Types of interventions</h4> <p>We considered all trials of treatment with any oral antiviral licensed for the treatment of herpes simplex infection in immunocompetent participants. Antivirals include aciclovir; valaciclovir, which is a prodrug of aciclovir; and famciclovir, which is a prodrug of penciclovir. We considered trials where participants received antiviral therapy alone or in combination with any other treatment versus placebo or any other treatment. </p> </section> <section id="CD001869-sec-0048"> <h4 class="title">Types of outcome measures</h4> <p>We have described changes to outcome measures in this and previous versions of the review in <a href="#CD001869-sec-0130">Differences between protocol and review</a>. </p> <section id="CD001869-sec-0049"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD001869-list-0001"> <li> <p>Incomplete recovery of facial function at the end of study, measured using a validated rating scale </p> </li> </ul> </p> </section> <section id="CD001869-sec-0050"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001869-list-0002"> <li> <p>Motor synkinesis or crocodile tears at the end of the study</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Incomplete recovery at month six in severe cases</p> </li> </ul> </p> <p>Some trials have reported other symptoms (pain, discomfort, and embarrassment) as outcomes, but we did not consider them in this review. </p> </section> </section> </section> <section id="CD001869-sec-0051"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001869-sec-0052"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Neuromuscular Information Specialist searched the following databases.</p> <p> <ul id="CD001869-list-0003"> <li> <p>The Cochrane Neuromuscular Specialised Register via the Cochrane Register of Studies (CRS‐Web) (31 July 2019; <a href="./appendices#CD001869-sec-0116">Appendix 1</a>). </p> </li> <li> <p>The Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies (CRS‐Web) (31 July 2019; <a href="./appendices#CD001869-sec-0117">Appendix 2</a>). </p> </li> <li> <p>MEDLINE (1946 to 30 July 2019; <a href="./appendices#CD001869-sec-0118">Appendix 3</a>). </p> </li> <li> <p>Embase (1974 to 29 July 2019; <a href="./appendices#CD001869-sec-0119">Appendix 4</a>). </p> </li> <li> <p>LILACS (1982 to 30 July 2019).</p> </li> </ul> </p> <p>We searched for registered trials on:</p> <p> <ul id="CD001869-list-0004"> <li> <p>ClinicalTrials.gov (June 2019; <a href="http://www.ClinicalTrials.gov" target="_blank">www.clinicaltrials.gov</a>; Appendix 6); </p> </li> <li> <p>Australian New Zealand Clinical Trials Registry (June 2019; <a href="http://www.anzctr.org.au" target="_blank">www.anzctr.org.au</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (June 2019; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en</a>; Appendix 7). </p> </li> </ul> </p> </section> <section id="CD001869-sec-0053"> <h4 class="title">Searching other resources</h4> <p>We also reviewed the bibliographies of the identified trials and contacted trial authors and known experts in the field and relevant drug companies to identify additional published or unpublished data. </p> </section> </section> <section id="CD001869-sec-0054"> <h3 class="title" id="CD001869-sec-0054">Data collection and analysis</h3> <p>We conducted the following four comparisons.</p> <p> <ul id="CD001869-list-0005"> <li> <p>Antiviral treatment in combination with corticosteroids versus corticosteroid treatment alone or in combination with placebo </p> </li> <li> <p>Antiviral treatment alone or in combination with placebo versus placebo or no treatment</p> </li> <li> <p>Antiviral treatment alone or in combination with placebo versus corticosteroid treatment alone or in combination with placebo </p> </li> <li> <p>Antiviral treatment in combination with corticosteroids versus placebo or no treatment</p> </li> </ul> </p> <section id="CD001869-sec-0055"> <h4 class="title">Selection of studies</h4> <p>Two review authors working in pairs (IG and VM) scrutinised titles and abstracts for potentially eligible studies. Both review authors independently assessed each full‐text paper for eligibility and selected studies for inclusion. We had no disagreements about inclusion. FS supervised all steps of the study selection. </p> </section> <section id="CD001869-sec-0056"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (IG and VM) extracted data onto a data extraction form and double‐checked data extraction in pairs. They agreed data input into the Cochrane authoring and statistical software, Review Manager 5 (<a href="./references#CD001869-bbs2-0070" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). They discussed any disagreements with a third review author (FD) to reach a resolution. We arranged translation of papers where necessary. </p> </section> <section id="CD001869-sec-0057"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (IG and VM) independently assessed the risk of bias in included studies using the 'Risk of bias' methodology described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001869-bbs2-0051" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). FD reviewed the 'Risk of bias' assessments to achieve agreement where there were differences. The review authors considered methods of randomisation and allocation concealment, blinding (of treatment administrator and participants, and outcome assessors), selective outcome reporting (for example, failure to report adverse events), and incomplete outcome data (i.e. dropouts). We assessed each trial as at high, low, or unclear risk of bias for each of these criteria. </p> </section> <section id="CD001869-sec-0058"> <h4 class="title">Measures of treatment effect</h4> <p>All our outcomes were dichotomous. We analysed the data as risk ratios (RRs) with corresponding 95% confidence intervals (CIs). </p> <p>When comparing studies that used different symptom scales to assess the primary outcome, incomplete recovery, we used the House‐Brackmann scale when available (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>), as this was used most widely and could be compared with other scales. The main outcome in all trials was complete recovery. For this review, the review authors calculated the number of participants with incomplete recovery by subtracting the number of participants with complete recovery from the number of participants in the reference group. </p> <p>When assessing adverse events, we used the number of participants affected as opposed to the number of events, to facilitate data comparison. </p> <section id="CD001869-sec-0059"> <h5 class="title">'Summary of findings' table</h5> <p>We created a 'Summary of findings' table for the comparison 'antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment'. We presented this single comparison because corticosteroids are known to be effective, and the main focus of this update, as for the previous version, was to determine whether adding antivirals to corticosteroid treatment provides additional benefit. We presented the following outcomes. </p> <p> <ul id="CD001869-list-0006"> <li> <p>Incomplete recovery at the end of the study (House‐Brackmann scale; <a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>) </p> </li> <li> <p>Motor synkinesis or crocodile tears at the end of the study (House‐Brackmann scale)</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> <p>We used the five GRADE considerations (risk of bias, inconsistency of effect, imprecision, indirectness, and publication bias) to assess the certainty of a body of evidence (studies that contribute data for the prespecified outcomes) using the <a href="./references#CD001869-bbs2-0048" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version (accessed prior to 30 July 2018). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a> computer programme. We started with a judgement for RCTs at high certainty and downgraded the evidence one level to moderate certainty, two levels to low certainty, and three levels to very low certainty according to the GRADE criteria. For any single consideration, we downgraded the evidence once, if present, to a serious degree and twice, if very serious. We employed methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001869-bbs2-0051" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), using GRADEpro software (<a href="./references#CD001869-bbs2-0048" title="McMaster University (developed by Evidence Prime). GRADEpro GDT. Version (accessed prior to 30 July 2018). Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. ">GRADEpro GDT 2015</a>). We justified all decisions to downgrade or upgrade the certainty of evidence using footnotes. </p> </section> </section> <section id="CD001869-sec-0060"> <h4 class="title">Unit of analysis issues</h4> <p>Each of the included studies carried out randomisation at the participant level. Twelve trials used a simple parallel‐group design (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Adour-1996" target="_blank">Adour 1996</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Li--1997" target="_blank">Li 1997</a>; <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Hato-2007" target="_blank">Hato 2007</a>;<a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>; <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-V_x00e1_zquez-2008" target="_blank">Vázquez 2008</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Yeo-2008" target="_blank">Yeo 2008</a>; <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>; <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Lee-2013" target="_blank">Lee 2013</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>). Two trials used a factorial design (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). </p> <p>For studies with a factorial design, we aggregated groups according to whether or not antivirals were administered. We have described details in the <a href="./full#CD001869-sec-0067">Results</a>. </p> </section> <section id="CD001869-sec-0061"> <h4 class="title">Dealing with missing data</h4> <p>We contacted authors of three studies for additional data that were required for analysis but which were not provided in their papers (<a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>), but only one responded with unpublished data (<a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>). We used the <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a> data provided in previous versions of this review. </p> </section> <section id="CD001869-sec-0062"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I² statistic to assess heterogeneity among the included studies in each analysis. If we found substantial unexplained heterogeneity, we reported it and explored possible causes according to the subgroup analyses. </p> </section> <section id="CD001869-sec-0063"> <h4 class="title">Assessment of reporting biases</h4> <p>We produced a funnel plot to assess the likelihood of publication and small‐study bias as there were sufficient studies in our antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment incomplete recovery analysis (<a href="./references#CD001869-bbs2-0044" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. [PUBMED: 9310563] ">Egger 1997</a>). </p> </section> <section id="CD001869-sec-0064"> <h4 class="title">Data synthesis</h4> <p>We calculated a treatment effect using the Mantel‐Haenszel method (<a href="./references#CD001869-bbs2-0045" title="EggerM , Davey SmithG , AltmanDG . Systematic Reviews in Health Care: Meta‐Analysis in Context. 6th Edition. London: BMJ Books, 2007. [ISBN: 978‐0‐7279‐1488‐0] ">Egger 2007</a>). We used the random‐effects model where we found marked heterogeneity (I² = 40% or greater) between studies. If we had found little or no heterogeneity, we would have used a fixed‐effect analysis. </p> </section> <section id="CD001869-sec-0065"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected heterogeneity in the effect estimates for incomplete recovery due to the following factors and conducted a subgroup analysis when the published studies or study authors provided sufficient data. </p> <p> <ul id="CD001869-list-0007"> <li> <p>The investigated corticosteroid was prednisolone; however, different antivirals were used. Most trials combined prednisolone with aciclovir, but some trials used valaciclovir or famciclovir. We performed subgroup analysis for each antiviral to assess potential differences in participant response to the three different antiviral medications. </p> </li> <li> <p>We planned to investigate whether time to treatment had an influence on incomplete recovery, when data were available. </p> </li> </ul> </p> <p>Some studies included participants with a broad range of symptom severity, while others included severe cases only. We performed an additional antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment analysis for incomplete recovery of people with severe Bell's palsy at baseline, using data from four trials. Severe Bell's palsy was defined as severe‐to‐complete facial paralysis, graded as equal to or greater than V in the House‐Brackmann grading system (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>; <a href="#CD001869-tbl-0002">Table 1</a>), equal to or less than 20 in the Sunnybrook score (<a href="./references#CD001869-bbs2-0071" title="RossBG , FradetG , NedzelskiJM . Development of a sensitive clinical facial grading system. Otolargynology ‐ Head and Neck Surgery1996;114(3):380‐6. [PUBMED: 8649870] ">Ross 1996</a>; <a href="#CD001869-tbl-0003">Table 2</a>), and equal to or less than 20 in the Yanagihara score (<a href="./references#CD001869-bbs2-0076" title="YanagiharaN , HatoN . Assessment of facial nerve function following acoustic neuroma surgery: facial nerve grading system. In: KanzakiJ , TosM , SannaM , MoffatDA , KunihiroT , InoueY editor(s). Acoustic Neuroma. Consensus on Systems for Reporting Results. 1st Edition. Vol. 10, Tokyo: Springer Japan, 2003:91‐8. [DOI: 10.1007/978‐4‐431‐53942‐116] ">Yanagihara 2003</a>; <a href="#CD001869-tbl-0004">Table 3</a>). We did not perform an analysis of non‐severe cases. </p> <div class="table" id="CD001869-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">House‐Brackmann Scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild dysfunction; slight weakness noticeable only on close inspection; may have slight synkinesis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate dysfunction; obvious but not disfiguring difference between the 2 sides; noticeable but not severe synkinesis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderately severe dysfunction; obvious weakness or disfiguring asymmetry, or both</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only barely perceptible motion</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No movement</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><a href="./references#CD001869-bbs2-0053" title="HouseJW . Facial nerve grading systems. Laryngoscope1983;93:1056‐69. ">House 1983</a>; <a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a> </p> </div> </div> <div class="table" id="CD001869-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sunnybrook Scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Facial grading system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Resting symmetry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symmetry of voluntary movement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Synkinesis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Compared to normal side</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Degree of muscle excursion compared to normal side</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Degree of involuntary muscle contraction associated with each expression</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Eye</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p><b>Standard expressions</b> </p> <p>Forehead wrinkle</p> <p>Gentle eye closure</p> <p>Open mouth smile</p> <p>Snarl</p> <p>Lip pucker</p> <p>Score each out of 5, where 5 is normal and 1 is gross asymmetry/no movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p><b>Standard expressions</b> </p> <p>Forehead wrinkle</p> <p>Gentle eye closure</p> <p>Open mouth smile</p> <p>Snarl</p> <p>Lip pucker</p> <p>Score each facial movement listed under standard expressions on a scale 0 to 3, where 0 is no asymmetry and 3 is severe asymmetry </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal = 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Narrow = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wide =1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eyelid surgery = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Cheek</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal = 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absent = 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less pronounced = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>More pronounced =1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Mouth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal = 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corner drooped =1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corner pulled up/out = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resting symmetry score x 5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Voluntary movement score</b> </p> <p><b>Total x 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Synkinesis score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Voluntary movement score ‐ resting symmetry score ‐ synkinesis score = composite Score</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Weighted regional evaluation using five separate expressions. Composite score from 0 (total paralysis) to 100 (normal function) (<a href="./references#CD001869-bbs2-0071" title="RossBG , FradetG , NedzelskiJM . Development of a sensitive clinical facial grading system. Otolargynology ‐ Head and Neck Surgery1996;114(3):380‐6. [PUBMED: 8649870] ">Ross 1996</a>). </p> </div> </div> <div class="table" id="CD001869-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Yanagihara Scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Degree of paralysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> <p>normal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> <p>slight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> <p>moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> <p>severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0</b> </p> <p>total</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At rest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wrinkle forehead</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blink</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal closure of eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Forced closure of eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Closure of eye on involved side</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wrinkle nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whistle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depress lower lip/ blow out cheek</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>10 separate categories of function, each scored 0 (total paralysis) to 4 (normal), then summed, giving a total score from 0 (total paralysis) to 40 (normal function) (<a href="./references#CD001869-bbs2-0074" title="YanagiharaN . Grading of facial palsy. Third international symposium on facial nerve surgery; 1976 Aug 9‐12; Zurich. Birmingham (AL): Aesculapius, 1977:533‐5. ">Yanagihara 1977</a>). </p> </div> </div> </section> <section id="CD001869-sec-0066"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to investigate:</p> <p> <ul id="CD001869-list-0008"> <li> <p>the effects of bias by excluding trials that had a high or unclear risk of bias in at least five categories; </p> </li> <li> <p>whether our conclusions were altered when we excluded studies with a follow‐up of less than six months; and </p> </li> <li> <p>the robustness of the results by changing between a fixed‐effect model and a random‐effects model. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001869-sec-0067" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001869-sec-0067"></div> <section id="CD001869-sec-0068"> <h3 class="title">Description of studies</h3> <section id="CD001869-sec-0069"> <h4 class="title">Results of the search</h4> <p>The previous version of the review included 10 studies and we added four studies that we had previously excluded. We found 222 records through database searching for this update and none through other sources. After removal of duplicates, we screened 183 records and excluded 149 records based on their titles and abstracts. After checking the full texts, we excluded 20 full‐text articles. We included 14 studies (which were reported in 14 separate publications) in the review, and included all 14 in quantitative synthesis (meta‐analysis). (<a href="#CD001869-fig-0001">Figure 1</a>). We did not find any ongoing studies in the World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en</a>). </p> <div class="figure" id="CD001869-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001869-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001869-sec-0070"> <h4 class="title">Included studies</h4> <p>We added four RCTs with 208 participants to the previous version of this review, which had 10 trials and 2280 participants. The newly added trials were <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>, <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>, <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> and <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>. Two trials have been published since previous searches in the 2015 review (<a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>). Although we excluded <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a> and <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> from the previous update (<a href="./references#CD001869-bbs2-0080" title="GagyorI , MadhokVB , DalyF , SomasundaraD , SullivanM , GammieF , et al. Antiviral treatment for Bell's palsy (idiopathic facial paralysis). Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD001869.pub8; PUBMED: 26559436 ] ">Gagyor 2015c</a>), due to their high or unclear risk of bias, we included both studies in the current analysis, and assessed the 'Risk of bias' and the certainty of evidence, as recommended by the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001869-bbs2-0051" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> <section id="CD001869-sec-0071"> <h5 class="title">Diagnostic criteria</h5> <p>Thirteen studies gave adequate information (<a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>; <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>; <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>; <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>; <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>; <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a>; <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>; <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>; <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>). All studies explicitly mentioned a diagnosis of Bell's palsy and stated that they had considered and excluded other causes of facial palsy. Three trials, <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>, <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a> and <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>, retrospectively excluded participants on the basis of positive serology for herpes simplex or varicella zoster virus, or due to other exclusion criteria. <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a> excluded participants who did not fulfil inclusion criteria, without specifying the reasons. Two studies mentioned referral to specialists for diagnostic confirmation (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> excluded people with mild to moderate Bell's palsy. The remaining study, <a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a>, stated that participants were diagnosed with Bell's palsy, but did not give any further information. </p> </section> <section id="CD001869-sec-0072"> <h5 class="title">Outcome criteria</h5> <p>All studies used referenced facial function scoring systems to grade recovery from facial paralysis. <a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a> and <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a> used the Facial Paralysis Recovery Profile (<a href="./references#CD001869-bbs2-0034" title="AdourKK , SwansonPJJr . Facial paralysis in 403 consecutive patients: emphasis on treatment response in patients with Bell's palsy. Transactions ‐ American Academy of Ophthalmology and Otolaryngology1971;75(6):1284‐301. ">Adour 1971</a>), and <a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a> also used the Facial Paralysis Recovery Index (<a href="./references#CD001869-bbs2-0035" title="AdourKK , WingerdJ . Idiopathic facial paralysis (Bell's palsy): factors affecting severity and outcome in 446 patients. Neurology1974;24(12):1112‐6. ">Adour 1974</a>). <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a> and <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a> used the Yanagihara scoring system (<a href="./references#CD001869-bbs2-0076" title="YanagiharaN , HatoN . Assessment of facial nerve function following acoustic neuroma surgery: facial nerve grading system. In: KanzakiJ , TosM , SannaM , MoffatDA , KunihiroT , InoueY editor(s). Acoustic Neuroma. Consensus on Systems for Reporting Results. 1st Edition. Vol. 10, Tokyo: Springer Japan, 2003:91‐8. [DOI: 10.1007/978‐4‐431‐53942‐116] ">Yanagihara 2003</a>), which has a validated system for conversion to the House‐Brackmann scale (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>). <a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>, <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>, <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>, <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>, <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>, <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>, <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>, <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>, and <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> presented results using the House‐Brackmann scale. <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> and <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> supplemented this with use of the Sunnybrook scale to minimise the effects of inter‐rater variability (<a href="./references#CD001869-bbs2-0071" title="RossBG , FradetG , NedzelskiJM . Development of a sensitive clinical facial grading system. Otolargynology ‐ Head and Neck Surgery1996;114(3):380‐6. [PUBMED: 8649870] ">Ross 1996</a>). <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a> used a facial grading scale related to the Sunnybrook scale (<a href="./references#CD001869-bbs2-0071" title="RossBG , FradetG , NedzelskiJM . Development of a sensitive clinical facial grading system. Otolargynology ‐ Head and Neck Surgery1996;114(3):380‐6. [PUBMED: 8649870] ">Ross 1996</a>). </p> <p>The 14 studies in the current review included 2488 participants (see <a href="./references#CD001869-sec-0132" title="">Characteristics of included studies</a>). </p> <p><a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a> was a single‐centre study that recruited 119 participants, of whom 99 were included in the published analysis. The study was double‐blind and placebo‐controlled. Participants were recruited within three days or less of onset of paralysis and received either aciclovir and prednisolone or placebo and prednisolone. The study duration was four months; participants were reviewed at two weeks, two months, and four months. The Facial Paralysis Recovery Index was used to measure facial function; the primary trial outcome was incomplete recovery defined by a Facial Paralysis Recovery Index of 7 or less. </p> <p><a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a> recruited 113 participants and included 101 participants in the final analysis. Participants were randomly assigned to treatment. Baseline assessment was carried out within 48 hours of the onset of symptoms. Participants received either aciclovir for 10 days or prednisolone for 16 days (reducing dose). Reviews were scheduled for one, three, six, and 12 weeks after initial contact, with further contact if persistent incomplete recovery was noted. The primary study outcome was recovery, as defined by a House‐Brackmann scale of 2 or less (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>), or a Facial Paralysis Recovery Profile (<a href="./references#CD001869-bbs2-0035" title="AdourKK , WingerdJ . Idiopathic facial paralysis (Bell's palsy): factors affecting severity and outcome in 446 patients. Neurology1974;24(12):1112‐6. ">Adour 1974</a>) of 8 or more. The report did not give the final length of follow‐up, but stated that it continued "until complete recovery or stabilization of the paralysis". </p> <p><a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a> recruited 51 participants within four days of onset of Bell's palsy. Participants were randomly assigned into two groups, who received either aciclovir plus prednisolone or prednisolone. Good recovery was defined as a House‐Brackmann scale of 1 or 2 at month six (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>). Li 1997 reported outcomes for 46 participants; five were lost to follow‐up. </p> <p><a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a> randomised 296 participants within seven days after onset, using sealed envelopes into two treatment groups: valaciclovir with prednisolone or placebo with prednisolone. The final analysis included 221 participants. Administrators and those assessing recovery status were not blinded to the treatment allocation, but participants were blinded to the treatment received. Disease severity was assessed using the Yanagihara 40‐point scoring system (<a href="./references#CD001869-bbs2-0076" title="YanagiharaN , HatoN . Assessment of facial nerve function following acoustic neuroma surgery: facial nerve grading system. In: KanzakiJ , TosM , SannaM , MoffatDA , KunihiroT , InoueY editor(s). Acoustic Neuroma. Consensus on Systems for Reporting Results. 1st Edition. Vol. 10, Tokyo: Springer Japan, 2003:91‐8. [DOI: 10.1007/978‐4‐431‐53942‐116] ">Yanagihara 2003</a>); participants were considered to have completely recovered if they attained a score greater than 36. Participants were assessed at onset and monthly thereafter for either six months or until completely recovered, if recovery occurred before six months. </p> <p><a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a> recruited 150 participants who were treated within seven days of onset and randomised using sealed envelopes into two treatment groups: valaciclovir plus prednisolone or prednisolone alone. There was inadequate clinician blinding. Kawaguchi and colleagues provided unpublished data on incomplete recovery for a previous update. Participants were assessed at one, two, three, four, five, and six months after inclusion using the Yanagihara scale (<a href="./references#CD001869-bbs2-0076" title="YanagiharaN , HatoN . Assessment of facial nerve function following acoustic neuroma surgery: facial nerve grading system. In: KanzakiJ , TosM , SannaM , MoffatDA , KunihiroT , InoueY editor(s). Acoustic Neuroma. Consensus on Systems for Reporting Results. 1st Edition. Vol. 10, Tokyo: Springer Japan, 2003:91‐8. [DOI: 10.1007/978‐4‐431‐53942‐116] ">Yanagihara 2003</a>). We could not contact the authors to obtain data for subsequent updates, but we included the data published in the earlier version of the review. </p> <p><a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a> recruited 551 participants, who were treated within 72 hours of onset. Participants were randomised by a dedicated remote telephone computerised mechanism, in a two‐stage process, into four treatment groups: aciclovir with prednisolone, aciclovir with placebo, placebo with prednisolone, or double placebo, in a factorial design. The trial was blinded for administrator, participant, and assessment of recovery status until the end of follow‐up. Participants were assessed at onset, after three months and, if still unwell at three months, and after nine months. Recovery status was measured using the House‐Brackmann scale (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>), with complete recovery defined as House‐Brackmann Grade 1. Data analysis included an assessment of treatment interaction. <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a> reported final outcomes on 496 completed participants at three months and nine months, in treatment groups that were aggregated, as for <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>. </p> <p><a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> recruited 829 participants, who were treated within 72 hours of onset and randomised in a two‐stage process by a computerised mechanism into four treatment groups: valaciclovir with prednisolone, valaciclovir with placebo, placebo with prednisolone, or double placebo, in a factorial design. The trial was double‐blind (administrator and participant) for assessment of recovery status until the end of follow‐up. Participants were assessed at onset, after two weeks (11 to 17 days), and after one, two, three, six, and 12 months. The disease status was measured using the House‐Brackmann grading system (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>), and the Sunnybrook scale (<a href="./references#CD001869-bbs2-0071" title="RossBG , FradetG , NedzelskiJM . Development of a sensitive clinical facial grading system. Otolargynology ‐ Head and Neck Surgery1996;114(3):380‐6. [PUBMED: 8649870] ">Ross 1996</a>). Complete recovery status was defined by a Sunnybrook score of 100 and House‐Brackmann Grade 1. Time to recovery was estimated. Data analysis included an assessment of treatment interaction. For this review, we analysed the recovery rates 12 months after the onset of facial palsy, and defined complete recovery as a House‐Brackmann Grade 1. </p> <p><a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a> included 167 participants with facial paralysis, aged 18 years and older, who were treated within five days after onset. Participants were randomised in two parallel groups: those admitted on even dates were assigned to prednisone (10 days), participants admitted on odd dates were randomised to prednisone and famciclovir (7 days). Treatment was administered unblinded. Of the 167 participants randomised, 50 were lost to follow‐up, and only 117 participants were analysed. Although the main outcome was defined as complete recovery at three months, only 47 were assessed as planned. The rest of the study participants returned before month three or after month 12. Data from these 47 participants were sent by the trial author. The assessors in the trial used the House‐Brackman scale or a similar score and complete recovery was not defined. </p> <p><a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a> included 42 participants and reported outcomes at six and 12 months using the Sunnybrook Facial Grading System (<a href="./references#CD001869-bbs2-0071" title="RossBG , FradetG , NedzelskiJM . Development of a sensitive clinical facial grading system. Otolargynology ‐ Head and Neck Surgery1996;114(3):380‐6. [PUBMED: 8649870] ">Ross 1996</a>). Scores greater than 90 were defined as a satisfactory recovery. Participants in the intervention group were treated with prednisone and valaciclovir and in the control group with prednisone and placebo. The main study outcome was the proportion of participants with total recovery at six months' follow‐up in each group, and average time to recovery in each group. </p> <p><a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a> recruited 91 participants who were randomised to receive either aciclovir and prednisolone or prednisolone alone. Participants also received physical therapy and plasma volume expanders as adjuncts. The trial was double‐blind and investigators followed up participants for six months, or until complete recovery. Recovery was assessed using the House‐Brackmann scale and was defined as a House‐Brackmann scale of 2 or less (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>). </p> <p><a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> carried out a randomised, controlled, open‐label study with clinic patients aged 15 years and older who had unilateral facial paralysis of unknown cause. Participants were quasi‐randomised, based on odd and even numbers, and were treated either with famiciclovir (5 days) plus prednisolone (7 days), or with prednisolone alone (7 days). Of the 107 participants recruited, 30 had exclusion criteria and nine were lost to follow‐up, so data from 68 patients were analysed. Participants were assessed at baseline using the House‐Brackman scale and were followed up one week, one month and three months after inclusion. Complete recovery was defined as House‐Brackman scale Grade 1. </p> <p><a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a> was a RCT in participants with severe‐to‐complete Bell's palsy, which used the House‐Brackmann scale for assessment (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>). The trial included 201 participants with a score of 5 or more. After randomisation into two groups, participants received either famciclovir plus prednisolone together, or prednisolone alone. Recovery was designated as a score of 1 or 2 on the House‐Brackmann scale at month six. </p> <p><a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> randomised 43 children, aged from 2 to 18 years, with unilateral Bell's palsy in two parallel groups. Participants were treated within three days after onset of Bell's palsy with either prednisolone and aciclovir or prednisolone only for seven days. The randomisation method was not stated. This open‐label trial did not use a placebo. The trial assessed the severity of Bell's palsy by the House‐Brackman scale. Complete recovery was defined as Grade 1. Participants were assessed at onset, four weeks, and three months after onset. </p> <p><a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> recruited 65 people with Bell's palsy, between 18 and 60 years old, and excluded 15 people with mild and moderate Bell's palsy. The 50 included participants were randomised in two groups using serially‐numbered, opaque, closed envelopes. Participants began treatment with prednisolone and aciclovir or prednisolone alone within three days after onset and treatment lasted seven days for prednisolone, and five days for aciclovir. The trial authors stated that the study was blinded, but did not use a placebo. Outcome data were assessed at baseline, two weeks, two months, and three months after inclusion, using the House‐Brackman scale. Complete recovery was defined as Grades 1 and 2. </p> </section> </section> <section id="CD001869-sec-0073"> <h4 class="title">Excluded studies</h4> <p>The authors of the previous version of this review excluded <a href="./references#CD001869-bbs2-0017" title="AntunesML , FukudaY , TestaJRG . Clinical treatment of Bell's palsy: comparative study among valaciclovir plus deflazacort, deflazacort and placebo [Tratamento clinico da paralisia de Bell: estudo comparativo com o uso de valaciclovir mais deflazacort versus deflazacort versus placebo]. Acta Associação William House de Otologia2000;19(2):68‐75. ">Antunes 2000</a> because of incomplete data in 44 participants. Despite our attempts to contact the authors, there was still insufficient information for the data to be usefully included in analyses. </p> <p>The authors of a previous version of this review reassessed the inclusion of the two studies that were awaiting assessment (<a href="./references#CD001869-bbs2-0020" title="deAquinoJE , Cruz FilhoNA . Comparative study of three types of treatment of idiopathic facial palsy (Bell) [Estudo comparativo com tres tipos de tratamento clinico na paralisa facial idiopatica (Bell)]. Acta Associação William House de Otologia2001;20(4):195‐200. [lil‐299927] ">de Aquino 2001</a>; <a href="./references#CD001869-bbs2-0028" title="RoyA , JoseJ , KamathV , MatthewT . Efficacy of aciclovir and methylprednisolone versus methylprednisolone alone in the treatment of Bell's palsy. Journal of the Neurological Sciences2005;238(Suppl 1):S207‐8. ">Roy 2005</a>). Dr D Allen, the author of a previous version of this review, attempted to contact the lead author of <a href="./references#CD001869-bbs2-0020" title="deAquinoJE , Cruz FilhoNA . Comparative study of three types of treatment of idiopathic facial palsy (Bell) [Estudo comparativo com tres tipos de tratamento clinico na paralisa facial idiopatica (Bell)]. Acta Associação William House de Otologia2001;20(4):195‐200. [lil‐299927] ">de Aquino 2001</a> for clarification of the data, but this was not forthcoming. We therefore excluded this trial because of a lack of adequate information. The latter study recruited 82 participants, of whom 18 dropped out, and compared aciclovir plus methylprednisolone to methylprednisolone alone, reporting no benefit from the addition of aciclovir. The authors did not provide outcome data in the abstract, which appeared in a journal supplement, and according to the search strategies employed, the trial has not been published to date as a full paper. We excluded this trial due to a lack of adequate information. </p> <p>A further study was classified as awaiting assessment in the previous version of this review (<a href="./references#CD001869-bbs2-0025" title="InanliS , TutkunA , OzturkO , BatmanC , UneriC , SehitogluMA . Idiopathic facial nerve paralysis treatment with acyclovir and prednisolone compared with prednisolone alone [Idiopatik fasiyal sinir paralizisinde prednizolon ve asiklovir Kkmbine tedavisinin prednizolon tedavisi ile karsilastirlmasi]. Turkish Archives of Otolaryngology2001;39(1):19‐24. ">Inanli 2001</a>). This paper was included in another systematic review and a meta‐analysis (<a href="./references#CD001869-bbs2-0042" title="deAlmeidaJR , Al KhaboriM , GuyattGH , WitterickIJ , LinVY , NedzelskiJM , et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta‐analysis. JAMA2009;302(9):985‐93. [PUBMED: 19724046] ">de Almeida 2009</a>; <a href="./references#CD001869-bbs2-0047" title="GoudakosJK , MarkouKD . Corticosteroids versus corticosteroids plus antiviral agents in the treatment of Bell Palsy: a systematic review and meta‐analysis. Archives of Otolaryngology ‐ Head &amp; Neck Surgery2009;135(6):558‐64. [PUBMED: 19528403] ">Goudakos 2009</a>). We excluded it from the current review because we could not find it in print or electronic form. See <a href="./references#CD001869-sec-0133" title="">Characteristics of excluded studies</a>. </p> <p>Overall, we excluded six studies for not being RCTs (<a href="./references#CD001869-bbs2-0024" title="IbarrondoJ , NavarreteML , EncarnaciónLF , QuesadaP , CrespoF , GarcíaM , et al. Treatment of idiopathic facial paralysis: corticoids versus acyclovir versus empirical treatment [Tratamiento de la paralisis facial idiopatica: corticoides versus aciclovir versus empirico]. Acta Otorrinolaringologica Espanola1999;50(2):118‐20. [PUBMED: 10217684] ">Ibarrondo 1999</a>; <a href="./references#CD001869-bbs2-0018" title="AxelssonS , LindbergS , Stjernquist‐DesatnikA . Outcome of treatment with valacyclovir and prednisone in patients with Bell's palsy. Annals of Otology, Rhinology and Laryngology2003;112(3):197‐201. ">Axelsson 2003</a>; <a href="./references#CD001869-bbs2-0022" title="HatoN , MatsumotoS , KisakiH , TakahashiH , WakisakaH , HondaN , et al. Efficacy of early treatment of Bell's palsy with oral acyclovir and prednisolone. Otology &amp; Neurotology2003;24(6):948‐51. [PUBMED: 14600480 ] ">Hato 2003</a>; <a href="./references#CD001869-bbs2-0023" title="HultcrantzM . Treatment of facial paresis ‐ evidence‐based recommendations [Behandling avfacialispares ‐ evidensbaserade rekommendationer]. Lakartidningen2005;102(10):744‐75. [PUBMED: 15839165] ">Hultcrantz 2005</a>; <a href="./references#CD001869-bbs2-0016" title="AhangarAA , HosseiniS , SaghebiR . Comparison of the efficacy of prednisolone versus prednisolone and acyclovir in the treatment of Bell's palsy. Neurosciences (Riyadh, Saudi Arabia)2006;11(4):256‐9. [PUBMED: 22266433] ">Ahangar 2006</a>; <a href="./references#CD001869-bbs2-0026" title="KangHM , JungSY , ByunJY , ParkMS , YeoSG . Steroid plus antiviral treatment for Bell's palsy. Journal of Internal Medicine2015;277(5):532‐9. [PUBMED: 25041467] ">Kang 2015</a>); three for having a very short follow‐up (<a href="./references#CD001869-bbs2-0029" title="ZhouP . Aciclovir in treating Bell's palsy. Chinese Journal of New Drugs and Clinical Remedies1999;18(1):13‐4. ">Zhou 1999</a>; <a href="./references#CD001869-bbs2-0019" title="ChenWL , YangZH , HuangZQ . Outcome of treatment of 46 patients with Bell's palsy with aciclovir and prednisone. Shanghai Kou Qiang Yi Xue [Shanghai Journal of Stomatology]2005;14(6):590‐2. ">Chen 2005</a>; <a href="./references#CD001869-bbs2-0021" title="FerreiraM , FirminoMJ , MarquesEA , SantosPC , DuarteJA . Are corticosteroids useful in all degrees of severity and rapid recovery of Bell’s palsy?. Acta Oto‐Laryngologica2016;136(7):736‐41. [PUBMED: 27003272] ">Ferreira 2016</a>); three because reports provided insufficient information to assess the methods or outcomes (<a href="./references#CD001869-bbs2-0017" title="AntunesML , FukudaY , TestaJRG . Clinical treatment of Bell's palsy: comparative study among valaciclovir plus deflazacort, deflazacort and placebo [Tratamento clinico da paralisia de Bell: estudo comparativo com o uso de valaciclovir mais deflazacort versus deflazacort versus placebo]. Acta Associação William House de Otologia2000;19(2):68‐75. ">Antunes 2000</a>; <a href="./references#CD001869-bbs2-0020" title="deAquinoJE , Cruz FilhoNA . Comparative study of three types of treatment of idiopathic facial palsy (Bell) [Estudo comparativo com tres tipos de tratamento clinico na paralisa facial idiopatica (Bell)]. Acta Associação William House de Otologia2001;20(4):195‐200. [lil‐299927] ">de Aquino 2001</a>; <a href="./references#CD001869-bbs2-0028" title="RoyA , JoseJ , KamathV , MatthewT . Efficacy of aciclovir and methylprednisolone versus methylprednisolone alone in the treatment of Bell's palsy. Journal of the Neurological Sciences2005;238(Suppl 1):S207‐8. ">Roy 2005</a>); three due to scarcity of data and the wrong study population (only an abstract was available and 15 of 45 participants had Ramsay Hunt syndrome, and were given intravenous therapy) (<a href="./references#CD001869-bbs2-0027" title="Ramos MacíasA , DeMiguel MartínezI , Martín SánchezAM , Gómez GonzálezJL , Martín GalánA . Incorporation of acyclovir in the treatment of peripheral paralysis. A study of 45 cases [Incorporación del aciclovir en el tratamiento de la parálisis periférica. Un estudio en 45 casos]. Acta Otorrinolaringológica Espanola1992;43(2):117‐20. [PUBMED: 1605959] ">Ramos Macias 1992</a>), another trial had a lack of outcome data, as described above (<a href="./references#CD001869-bbs2-0028" title="RoyA , JoseJ , KamathV , MatthewT . Efficacy of aciclovir and methylprednisolone versus methylprednisolone alone in the treatment of Bell's palsy. Journal of the Neurological Sciences2005;238(Suppl 1):S207‐8. ">Roy 2005</a>), one paper was not available (<a href="./references#CD001869-bbs2-0025" title="InanliS , TutkunA , OzturkO , BatmanC , UneriC , SehitogluMA . Idiopathic facial nerve paralysis treatment with acyclovir and prednisolone compared with prednisolone alone [Idiopatik fasiyal sinir paralizisinde prednizolon ve asiklovir Kkmbine tedavisinin prednizolon tedavisi ile karsilastirlmasi]. Turkish Archives of Otolaryngology2001;39(1):19‐24. ">Inanli 2001</a>); and we excluded one paper from the previous update, as the paper was found to be plagiarised and has since been retracted (<a href="./references#CD001869-bbs2-0015" title="AbdelghanyAM , KamelSB . Retracted: the effect of prednisolone and/or acyclovir in relation to severity of Bell's palsy at presentation. Egyptian Journal of Ear, Nose, Throat and Allied Sciences2013;14(3):155‐9. [DOI: https://doi.org/10.1016/j.ejenta.2013.04.003] AbdelghanyAM , KamelSB . Retraction notice to ‘‘The effect of prednisolone and/or acyclovir in relation to severity of Bell’s palsy at presentation” [Egypt. J. Ear NoseThroat Allied Sci 14(3) (2013) 155–9]. Egyptian Journal of Ear, Nose and Throat2017;18(3):329. [DOI: org/10.1016/j.ejenta.2013.04.003] ">Abdelghany 2013</a>). </p> <section id="CD001869-sec-0074"> <h5 class="title">Ongoing studies</h5> <p>We identified two trial reports in children with Bell's palsy in a search of ClinicalTrials.gov and the Australian New Zealand Clinical Trials Registry just prior to completion of the review (<a href="http://www.ClinicalTrials.gov" target="_blank">www.clinicaltrials.gov</a>; <a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en</a>). Both studies are still recruiting. See <a href="./references#CD001869-bbs1-0004" title="">Ongoing studies</a>. </p> </section> <section id="CD001869-sec-0075"> <h5 class="title">Studies awaiting classification</h5> <p>We found one trial in children and adults with Bell's palsy in a search of the World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/en/" target="_blank">www.who.int/ictrp/en</a>), which was characterised as completed. We contacted the authors for more information about the current status of the trial but did not receive a reply. See <a href="./references#CD001869-bbs1-0003" title="">Studies awaiting classification</a>. </p> </section> </section> </section> <section id="CD001869-sec-0076"> <h3 class="title">Risk of bias in included studies</h3> <p>We have summarised 'Risk of bias' assessments in <a href="#CD001869-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD001869-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="A summary of review authors' 'Risk of bias' assessments for included studies. Red = high risk of bias; yellow = unclear risk of bias; green = low risk of bias." data-id="CD001869-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>A summary of review authors' 'Risk of bias' assessments for included studies. Red = high risk of bias; yellow = unclear risk of bias; green = low risk of bias. </p> </div> </div> </div> <section id="CD001869-sec-0077"> <h4 class="title">Allocation</h4> <p>Three studies were at low risk of selection bias, being adequately randomised, with allocation concealment (<a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). </p> <p>Two other studies were at low risk of bias from the method of randomisation, but at high or unclear risk of bias from inadequate allocation concealment (<a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>; <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>). <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a> reported a later onset of the treatment in the combination treatment group, without significance. The trial used a simple randomisation generated by Microsoft Excel to intervention and control but the authors did not provide information on allocation concealment (<a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>). <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a> did not conceal allocation, the allocation envelope contained the name of the treatment group, Although this trial reported a significant difference between mean ages of the treatment groups, further analysis of the age distribution using the Chi² test revealed no significant difference. </p> <p>In seven studies, the risk of bias from the method of randomisation and allocation concealment were unclear (<a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>; <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>; <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>; <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a>; <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>). <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>, <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a>, <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a> and <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> did not describe the randomisation method or measures to conceal allocation. <a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a> used codes, but provided little information on randomisation. <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> and <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a> reported the use of envelopes, and in <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> these were serially‐numbered, opaque and closed, but the reports provided insufficient detail for a clear judgement. </p> <p><a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a> and <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> were at high risk of bias for randomisation as they used even and odd days or numbers to randomise the participants. In <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>, there were 25% more participants in the prednisolone group than in the combination treatment group. <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> included more participants with severe Bell's palsy in the combination treatment group than in the prednisolone alone group. <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a> was not blinded and unlikely to have concealed allocation. Allocation concealment in <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> was unclear. </p> </section> <section id="CD001869-sec-0078"> <h4 class="title">Blinding</h4> <p><a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996,</a><a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>, <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a> and <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> were described as double‐blind and placebo‐controlled trials and we assessed them at low risk of performance bias. All used placebo and described methods for adequate blinding of the trial drug. <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>, <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>, <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>, <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>, <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>, <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>, and <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> were open‐label and we assessed them at high risk of bias. <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a>, <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a> and <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> stated that the study was double‐blind; however, the text does not describe this and the trials were not placebo‐controlled, so we assessed their risk of bias for blinding (performance bias) as unclear. </p> <p>For blinding of the outcome assessor, we assessed two trials at low risk of bias (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). The remaining studies were at high or unclear risk of bias. </p> </section> <section id="CD001869-sec-0079"> <h4 class="title">Incomplete outcome data</h4> <p>All studies except <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a> and <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> reported frequencies, and often reasons, for failure to complete follow‐up. We assessed five trials at low risk for incomplete outcome data (<a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>). These trials reported a dropout rate of less than 10%. </p> <p>We assessed <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a> at unclear risk of bias due to a dropout rate of 10%. Two trials also reported a dropout rate of less than 10% but reasons for drop out were not given in the paper (<a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>; <a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>). We assessed these studies at unclear risk of bias for this reason, as for <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>. The remaining five studies were at high risk of bias in this category: <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Lee-2013" target="_blank">Lee 2013</a> reported a dropout rate of 13.1%, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Adour-1996" target="_blank">Adour 1996</a> 17%, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Hato-2007" target="_blank">Hato 2007</a> 25%, and <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> 27%. <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a> reported a loss to follow‐up rate of 30%, but for the current review, data from only 30% of the study population (participants assessed between 3 and 12 months) fulfilled the inclusion criteria of this review. None of the studies assessed as high and unclear risk of bias used the intention‐to‐treat approach to control this. </p> </section> <section id="CD001869-sec-0080"> <h4 class="title">Selective reporting</h4> <p>All studies except <a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a> and <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a> reported all intended primary outcomes. <a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a> failed to report on audiometry and stapedial reflex testing. <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> reported all primary outcomes; secondary outcomes were reported in later published papers (<a href="./references#CD001869-bbs2-0037" title="AxelssonS , BergT , JonssonL , EngströmM , KanervaM , Stjernquist‐DesatnikA . Bell's palsy ‐ the effect of prednisolone and/or valaciclovir versus placebo in relation to baseline severity in a randomised controlled trial. Clinical Otolaryngology2012;37(4):283‐90. [PUBMED: 22776019] ">Axelsson 2012</a>; <a href="./references#CD001869-bbs2-0039" title="BergT , BylundN , MarskE , JonssonL , KanervaM , HultcrantzM , et al. The effect of prednisolone on sequelae in Bell's palsy. Archives of Otolaryngology ‐ Head &amp; Neck Surgery2012;138(5):445‐9. [PUBMED: 22652942] ">Berg 2012</a>). <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a> reported the main outcome for all participants independently from the time of the assessment, and published data were insufficient to differentiate between those who were eligible to be included in this review (participants who were assessed within the defined time period of 3 to 12 months) and those who were not. <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> did not report baseline data. </p> <p>Seven studies did not report adverse events (<a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>; <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>; <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>; <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>; <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>). </p> </section> <section id="CD001869-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <section id="CD001869-sec-0082"> <h5 class="title">Statistical analysis</h5> <p>Twelve of the 14 studies analysed gave adequate detail; they clearly stated and then used appropriate statistical tests. We only scored <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a> 'unclear' in this category, as the authors did not adequately describe the tests used. We scored <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> 'high' for this and in addition due to baseline differences between groups at inclusion. </p> </section> <section id="CD001869-sec-0083"> <h5 class="title">Baseline differences between groups</h5> <p>Eight of the 14 trials were adequate in this category. <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a> found a significant difference in rates of hypertension between the two groups, but further analysis revealed that there was no significant difference in trial outcomes as a result. <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a> reported a significant difference between mean ages of the treatment groups, but further analysis of the age distribution using the Chi² test revealed no significant difference. <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a> reported a later onset of treatment in the combination treatment group, without significance but it was of unclear risk for excluding of two participants with adverse events in the steroid group (not clearly specified) from the analysis. </p> <p>We assessed two trials at unclear risk in this category: <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> reported only age and sex at baseline and there was a difference between the groups, and in <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a> there were 25% more participants in the prednisolone group than in the combination treatment group. We scored <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> as high risk of bias; it included more participants with severe Bell's palsy in the combination group than in the prednisolone alone group. </p> </section> </section> </section> <section id="CD001869-sec-0084"> <h3 class="title" id="CD001869-sec-0084">Effects of interventions</h3> <p>See: <a href="./full#CD001869-tbl-0001"><b>Summary of findings for the main comparison</b> Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment (AS versus OS) for Bell's palsy (idiopathic facial paralysis)</a> </p> <p>As the included trials reported different intervals and lengths of follow‐up, we performed the analyses on data reported at three months (<a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>; <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>), six months (<a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>; <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>; <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>; <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a>; <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>; <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>), nine months (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>), or 12 months (<a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>), after the start of treatment. </p> <p>For the subgroup analysis of incomplete recovery in participants with severe Bell's palsy at onset, we either extracted data at month six, in <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a> and <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>, or imputed data to month six, in <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a> and <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>. </p> <p>Throughout this section of the review, we utilised the following notation.</p> <p> <ul id="CD001869-list-0009"> <li> <p>AO: antiviral treatment alone or in combination with placebo</p> </li> <li> <p>AS: antiviral treatment in combination with corticosteroids</p> </li> <li> <p>OO: placebo or no treatment</p> </li> <li> <p>OS: corticosteroid treatment alone or in combination with placebo</p> </li> </ul> </p> <section id="CD001869-sec-0085"> <h4 class="title">Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS) </h4> <p>This comparison included 13 studies with 1729 participants (<a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a>; <a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>; <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>; <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>; <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>; <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a>; <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>; <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>; <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>). We restricted our main analyses to studies at low or unclear risk of bias in fewer than five domains. See <a href="./full#CD001869-tbl-0001">summary of findings Table for the main comparison</a>. </p> <section id="CD001869-sec-0086"> <h5 class="title">Incomplete recovery</h5> <p>Three studies comparing AS and OS were at high or unclear risk of bias in fewer than five categories (<a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). Pooled data from these three studies found no clear difference between AS and OS (risk ratio (RR) 0.81, 95% confidence interval (CI) 0.38 to 1.74; 3 trials, N = 766; random‐effects; low‐certainty evidence). The result showed substantial heterogeneity (Chi² = 5.30, df = 2 (P = 0.07); I² = 62%) and was imprecise, with a CI that encompassed effects in either direction (<a href="./references#CD001869-fig-0007" title="">Analysis 1.1</a>; <a href="#CD001869-fig-0003">Figure 3</a>). </p> <div class="figure" id="CD001869-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): sensitivity analysis based on risk of bias (excluding studies at high or unclear risk of bias in fewer than five domains), outcome: 1.1 Incomplete recovery at end of study." data-id="CD001869-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): sensitivity analysis based on risk of bias (excluding studies at high or unclear risk of bias in fewer than five domains), outcome: 1.1 Incomplete recovery at end of study. </p> </div> </div> </div> <p>When the analysis used all the available evidence, the rate of incomplete recovery was lower after AS than OS (RR 0.59, 95% CI 0.47 to 0.70; 13 trials, N = 1729; fixed‐effect; very low‐certainty evidence). Heterogeneity was substantial (Chi<sup>2</sup> = 20.03, df = 12 (P = 0.07), I² = 40%); we used the random‐effects model to adjust for this (RR 0.54, 95% CI 0.38 to 0.77; <a href="./references#CD001869-fig-0008" title="">Analysis 1.2</a>; <a href="#CD001869-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD001869-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data set)." data-id="CD001869-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data set). </p> </div> </div> </div> <p>We also investigated the effect of AS versus OS by performing a sensitivity analysis (on the whole data set) to investigate the effect of removing studies with a follow‐up of less than six months (i.e. <a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a>; <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>). We found that this did not substantially alter the findings (RR 0.65, 95% CI 0.45 to 0.94; Chi² = 12.75, df = 8 (P = 0.12); I² = 37%; 9 trials, N = 1469; random‐effects). </p> <section id="CD001869-sec-0087"> <h6 class="title">Subgroup analysis: effect of different antiviral agents</h6> <p>In our analysis of trials at lower risk of bias, we presented data for this outcome subgrouped by antiviral agent: aciclovir (<a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>), or valaciclovir (<a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). There were too few trials for reliable subgroup analysis (<a href="./references#CD001869-fig-0007" title="">Analysis 1.1</a>) </p> <p>We performed this subgroup analysis on the full data set: aciclovir (<a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a>; <a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>; <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a>; <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a>); famciclovir (<a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>; <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>; <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>); and valaciclovir (<a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>; <a href="./references#CD001869-bbs2-0013" title="VázquezMC , SánchezN , CalvoJ , PernaA . Efficacy of antiviral in Bell's palsy [Eficacia de los antivirales en la parálisis de Bell]. Revista Medica del Uruguay2008;24(3):167‐74. [LILACS 501670] ">Vázquez 2008</a>; <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>). Trials that studied the effects of aciclovir (RR 0.43, 95% CI 0.22 to 0.83; 6 trials, N = 580) and famiciclovir (RR 0.48, 95% CI 0.22 to 1.06; 3 trials, N = 321) showed large effects in favour of AS over OS. Yet, the valaciclovir subgroup showed a smaller effect in favour of AS over OS and more imprecision (RR 0.79, 95% CI 0.57 to 1.08; 4 trials, N = 828; <a href="./references#CD001869-fig-0008" title="">Analysis 1.2</a>). The statistical test for subgroup differences did not support a subgroup effect: Chi² = 3.44, df = 2 (P = 0.18); I² = 41.9%. </p> </section> <section id="CD001869-sec-0088"> <h6 class="title">Additional analysis: severe cases</h6> <p>For this comparison, we extracted data from four studies (<a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>; <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>). </p> <p>We restricted our main analysis to two studies at lower risk of bias (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). The proportion of participants with incomplete recovery showed no clear difference in the AS group versus the OS group among people with severe Bell's palsy (RR 0.82, 95% CI 0.57 to 1.17; 2 studies, N = 98; Chi² = 0.72, df = 1 (P = 0.40); I² = 0%; random‐effects; <a href="./references#CD001869-fig-0009" title="">Analysis 1.3</a>; <a href="#CD001869-fig-0005">Figure 5</a>). The result was imprecise but without statistical heterogeneity. </p> <div class="figure" id="CD001869-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 3 Antivirals plus corticosteroids versus placebo, outcome: 3.1 Incomplete recovery at end of study." data-id="CD001869-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 3 Antivirals plus corticosteroids versus placebo, outcome: 3.1 Incomplete recovery at end of study. </p> </div> </div> </div> <p>When the analysis used all the available evidence (i.e. also including <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a> and <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a>), the proportion of participants with incomplete recovery was slightly lower in the AS group versus the OS group in people with severe Bell's palsy. The result was also imprecise (RR 0.64, 95% CI 0.41 to 0.99; 4 trials, N = 478; random‐effects). Heterogeneity was moderate (Chi² = 5.2, P = 0.16, I² = 42%) (see <a href="./references#CD001869-fig-0010" title="">Analysis 1.4</a>). </p> </section> </section> <section id="CD001869-sec-0089"> <h5 class="title">Motor synkinesis or crocodile tears</h5> <p><a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a> and <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> provided data on motor synkinesis or crocodile tears, assessed at the end of the study. The analysis included 469 participants and showed that fewer participants experienced these long‐term sequelae after AS than after OS (RR 0.56, 95% CI 0.36 to 0.87; 2 trials, N = 469; Chi² = 0.25, df = 1 (P = 0.62); I² = 0%; fixed‐effect; moderate certainty‐evidence; <a href="./references#CD001869-fig-0011" title="">Analysis 1.5</a>). As both trials were of low risk of bias in most domains, we did not perform a sensitivity analysis. </p> </section> <section id="CD001869-sec-0090"> <h5 class="title">Adverse events</h5> <p>Four trials comparing AS versus OS reported on adverse events, reporting data from 945 participants (<a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>; <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>). </p> <p>The analysis including only the studies at a low risk of bias (i.e. <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a> and <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>), showed no clear difference between AS and OS in the number of participants experiencing adverse events (RR 1.17, 95% CI 0.81 to 1.69; 2 trials, N = 656; Chi² = 0.26, df = 1 (P = 0.61); I² = 0%; fixed‐effect; <a href="./references#CD001869-fig-0012" title="">Analysis 1.6</a>). </p> <p>The result using all the available evidence was similar to evidence from studies at low risk of bias, with no clear difference in the number of participants with adverse events between the AS and the OS group (RR 1.16, 95% CI 0.83 to 1.63; 4 trials, N = 945; Chi² = 0.39, df = 3 (P = 0.94); I² = 0%; fixed‐effect; very low‐certainty evidence; <a href="./references#CD001869-fig-0013" title="">Analysis 1.7</a>). </p> </section> </section> <section id="CD001869-sec-0091"> <h4 class="title">Antivirals versus corticosteroids (AO versus OS)</h4> <p>This comparison contained three studies (<a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>; <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). </p> <section id="CD001869-sec-0092"> <h5 class="title">Incomplete recovery</h5> <p>All three studies (768 participants) provided data for our primary outcome, incomplete recovery at the end of the study. </p> <p>Our primary analysis, which excluded <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a> due to a high or unclear risk of bias in five domains, produced a RR of 2.69, 95% CI 0.73 to 10.01; 2 studies, N = 667; Chi² = 7.41, df = 1 (P = 0.006); I² = 87%; random‐effects; <a href="./references#CD001869-fig-0014" title="">Analysis 2.1</a>). The result favoured corticosteroids; however heterogeneity was substantial and the CI did not exclude the possibility of no difference between the groups. </p> <p>Analysis of all three trials (i.e. including <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>), also found a greater proportion of participants treated with AO had incomplete recovery than those treated with OS. Initial calculations using the fixed‐effect model showed a RR of 1.96, 95% CI 1.48 to 2.59; 3 trials, N = 768, but with a high degree of heterogeneity (Chi² = 8.78, df = 2 (P = 0.01); I² = 77%). We repeated the analysis using the random‐effects model to adjust for this, and the RR was 2.82, 95% CI 1.09 to 7.32; <a href="./references#CD001869-fig-0015" title="">Analysis 2.2</a>). </p> </section> <section id="CD001869-sec-0093"> <h5 class="title">Motor synkinesis or crocodile tears</h5> <p><a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a> and <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> provided data for the outcome, motor synkinesis or crocodile tears at the end of the study. </p> <p>After removing <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a> (unclear or high risk of bias in 5 domains) the results from <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> showed that more participants had sequelae with AO than OS (RR 1.70, 95% CI 1.15 to 2.50; 1 trial, N = 371; <a href="./references#CD001869-fig-0016" title="">Analysis 2.3</a>). </p> <p>Analysis of the full data set including 472 participants also found more participants had sequelae after AO than OS (RR 1.52, 95% CI 1.08 to 2.12; 2 trials, N = 472; Chi² = 1.50, (P = 0.22); I² = 33%; fixed‐effect; <a href="./references#CD001869-fig-0017" title="">Analysis 2.4</a>). </p> </section> <section id="CD001869-sec-0094"> <h5 class="title">Adverse events</h5> <p>Two trials reported this outcome (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). </p> <p>Fewer participants experienced adverse events in the AO group than the OS group (RR 0.85, 95% CI 0.57 to 1.28; 2 trials, N = 658; Chi² = 0.05, df = 1 (P = 0.82); I² = 0%; fixed‐effect; very low‐certainty evidence; <a href="./references#CD001869-fig-0018" title="">Analysis 2.5</a>), but the CIs included the possibility of the opposite effect (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). Due to a low risk of bias in most domains of both trials, we did not perform a sensitivity analysis. </p> </section> </section> <section id="CD001869-sec-0095"> <h4 class="title">Antivirals plus corticosteroids versus placebo (AS versus OO)</h4> <p>This comparison contained two studies and outcome data on 658 participants (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). </p> <section id="CD001869-sec-0096"> <h5 class="title">Incomplete recovery</h5> <p>There was a large effect on the rates of incomplete recovery at the end of the study that favoured AS compared with OO (RR 0.56, 95% CI 0.42 to 0.76; 2 trials, N = 658; Chi² = 0.14, df = 1 (P = 0.71); I² = 0%; random‐effects; <a href="./references#CD001869-fig-0019" title="">Analysis 3.1</a>; <a href="#CD001869-fig-0005">Figure 5</a>). We did not perform a sensitivity analysis in this data set since the risk of bias was low in both included studies. </p> </section> <section id="CD001869-sec-0097"> <h5 class="title">Motor synkinesis or crocodile tears</h5> <p>One trial reported the effect of the intervention on motor synkinesis or crocodile tears (<a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>), and showed a reduction in the AS versus the OO group, with a RR of 0.37, 95% CI 0.23 to 0.59; 1 trial, N = 372; random‐effects; <a href="./references#CD001869-fig-0020" title="">Analysis 3.2</a>). </p> </section> <section id="CD001869-sec-0098"> <h5 class="title">Adverse events</h5> <p>Using the data from both trials, there was little or no difference between treatment with AS and OO in the proportion of participants with adverse events (RR 1.14, 95% CI 0.79 to 1.65; 2 trials, N = 649, Chi² = 0.13, df = 1 (P = 0.72); I² = 0%; fixed‐effect; <a href="./references#CD001869-fig-0021" title="">Analysis 3.3</a>). </p> </section> </section> <section id="CD001869-sec-0099"> <h4 class="title">Antivirals versus placebo (AO versus OO)</h4> <p>Two studies investigated this comparison (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). We did not perform a sensitivity analysis in this comparison, as both trials were at lower risk of bias. </p> <section id="CD001869-sec-0100"> <h5 class="title">Incomplete recovery</h5> <p>Two trials compared antivirals versus placebo without any complicating additional treatment (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). AO had no clear effect on the proportion of participants with incomplete recovery (RR 1.10, 95% CI 0.87 to 1.40; 2 trials, N = 658). There was imprecision and the heterogeneity was moderate (Chi² = 1.63, P = 0.20, I² = 39%; fixed‐effect; <a href="./references#CD001869-fig-0022" title="">Analysis 4.1</a>). </p> </section> <section id="CD001869-sec-0101"> <h5 class="title">Motor synkinesis or crocodile tears</h5> <p>Only <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> reported results for this outcome (RR 1.04, 95% CI 0.75 to 1.43; 1 trial, N = 373; random‐effects; <a href="./references#CD001869-fig-0023" title="">Analysis 4.2</a>. </p> </section> <section id="CD001869-sec-0102"> <h5 class="title">Adverse events</h5> <p>The proportion of participants who had adverse events was similar in the AO and OO groups, but the result was imprecise (RR 0.83, 95% CI 0.56 to 1.24; 2 trials, N = 651; Chi² = 0.33, df = 1 (P = 0.57); I² = 0%; fixed‐effect; <a href="./references#CD001869-fig-0024" title="">Analysis 4.3</a>). </p> </section> </section> <section id="CD001869-sec-0103"> <h4 class="title">Funnel plot</h4> <p>We included a funnel plot, which shows some asymmetry of the distribution of the studies. This suggests small‐study effects and may reflect differences in methodological quality or publication bias (<a href="#CD001869-fig-0006">Figure 6</a>). </p> <div class="figure" id="CD001869-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data set)." data-id="CD001869-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data set). </p> </div> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001869-sec-0104" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001869-sec-0104">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001869-sec-0166">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001869-sec-0104"></div> <section id="CD001869-sec-0105"> <h3 class="title" id="CD001869-sec-0105">Summary of main results</h3> <p>We identified 14 studies of antivirals in Bell's palsy that provided data for analyses. They included 2488 participants. We were unable to draw any conclusions from analysis of the 14 studies, as the certainty of evidence was very low, primarily due to study limitations and inconsistency. When we limited our analysis to data from three studies at lower risk of bias, results indicated that the combination of antivirals and corticosteroids may have little or no effect on rates of incomplete recovery compared to corticosteroids alone (see <a href="./full#CD001869-tbl-0001">summary of findings Table for the main comparison</a>). There was no clear difference in rates of incomplete recovery among participants with severe Bell's palsy in the group treated with the combination of antiviral treatment and corticosteroids versus those who received corticosteroid treatment alone or in combination with placebo, in contrast with results based on the full data set from people with severe disease, which found a slightly lower rate of incomplete recovery with antiviral treatment in combination with corticosteroids compared to corticosteroid treatment alone or in combination with placebo. </p> <p>The rate of incomplete recovery was higher in participants receiving antivirals alone or in combination with placebo than in those who received corticosteroids alone or in combination with placebo. The rate of incomplete recovery was lower with the combination of antivirals and corticosteroids than with placebo or no treatment, but antivirals alone or in combination with placebo had no clear effect compared with placebo or no treatment. For these outcomes, we analysed data from two or three trials only. Apart from the comparison of antivirals in combination with corticosteroids versus placebo or no treatment, the trials showed a moderate to high degree of heterogeneity and wide confidence intervals (CIs). </p> <p>Three studies evaluated sequelae (long‐term effects) of Bell's palsy, crocodile tears and motor synkinesis, at the end of the study. They found that there were probably fewer instances of long‐term sequelae in people who received the combination of antivirals and corticosteroids compared with the group who received corticosteroids alone or in combination with placebo (<a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). These sequelae were also less frequent in those who were treated with antivirals alone or in combination with placebo compared with corticosteroids alone or in combination with placebo (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Adour-1996" target="_blank">Adour 1996</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>), and in those treated with the combination of antivirals and corticosteroids compared with placebo or no treatment (<a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>). </p> <p>Data did not show clear differences in the adverse events in any of the comparisons.</p> </section> <section id="CD001869-sec-0106"> <h3 class="title" id="CD001869-sec-0106">Overall completeness and applicability of evidence</h3> <p>Although the number of included studies and participants have increased since the last update of this review, the additional studies did not contribute to the certainty of the evidence. The external validity of most evidence was low, which limited interpretation of the results. The heterogeneity found in analyses may be due to clinical variation, for example in participant characteristics, age, disease severity at baseline, delay in receiving treatment, or different type of antiviral agent used, and also different time points of measurements of the outcome. Heterogeneity was exacerbated in many studies by keeping the inclusion criteria fairly broad; this maximised data inclusion, and therefore power, but results must be interpreted with this in mind. Furthermore, the different definitions of severe Bell’s palsy in the trials, depending on the symptom scores should also be considered a potential source of heterogeneity. Other limitations are the high or unclear risk of bias in several domains and the small size of the majority of included trials. Given the likely overall small or absent effect of antivirals, it is unlikely that different antiviral compounds will have a significant effect on incomplete recovery at the end of the study, despite the difference in bioavailability (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Sullivan-2007" target="_blank">Sullivan 2007</a>). </p> <p>We found differences in severity at recruitment: <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Li--1997" target="_blank">Li 1997</a>, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Hato-2007" target="_blank">Hato 2007</a>, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-V_x00e1_zquez-2008" target="_blank">Vázquez 2008</a>, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Yeo-2008" target="_blank">Yeo 2008</a>, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Lee-2013" target="_blank">Lee 2013</a> and <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> included a more severe spectrum of palsy. <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Hato-2007" target="_blank">Hato 2007</a> and <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> stratified participants by severity of disease status at onset. <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a> found that in cases of complete or severe palsy, the recovery rate for the combination treatment was greater than for participants treated only with OS. <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Lee-2013" target="_blank">Lee 2013</a> included only severe cases and found a higher rate of recovery in the group receiving a combination treatment using famciclovir. <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> excluded patients with mild to moderate palsy and showed benefit from a combination treatment. In contrast, <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a> could not confirm these findings in treatment of participants with severe Bell's palsy, whereas in <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>, combined treatment with antivirals and corticosteroids showed increased rates of incomplete recovery over corticosteroids alone. The analysis of participants with severe Bell's palsy showed no clear effect of the combination treatment. </p> <p>We found variation in the clinical endpoints chosen as defining recovery: <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Sullivan-2007" target="_blank">Sullivan 2007</a>, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Engstr_x00f6_m-2008" target="_blank">Engström 2008</a>, <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a> and <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> used House‐Brackmann scale Grade 1 (<a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a>), while <a href="./references#CD001869-bbs2-0009" title="LiY , GaoP , MaoX , CaoP . Randomized clinical trial of acyclovir plus prednisone versus prednisone alone in Bell's palsy. Ceylon Journal of Medical Science1997;40(2):37‐41. ">Li 1997</a>, <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a>, <a href="./references#CD001869-bbs2-0008" title="LeeHY , ByunJY , ParkMS , YeoSG . Steroid‐antiviral treatment improves the recovery rate in patients with severe Bell's palsy. American Journal of Medicine2013;126(4):336‐41. [PUBMED: 23394867] ">Lee 2013</a> and <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> used House‐Brackmann scale Grade 1 and 2. <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a> did not define recovery. The other studies used a variety of different scales that show more or less equivalence to these. We have provided details of the symptoms scales and comparisons, where available (<a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#TBL-01" target="_blank">Table 1</a>, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#TBL-02" target="_blank">Table 2</a>, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#TBL-03" target="_blank">Table 3</a>). </p> <p>Equally, heterogeneity could be due to methodological or design differences in the studies, such as the method of randomisation, use of blinding, choice of outcome measures and recovery cut‐off points, or trial duration. In particular, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Li--1997" target="_blank">Li 1997</a>, <a href="./references#CD001869-bbs2-0002" title="DeDiegoJI , PrimMP , DeSarriaMJ , MaderoR , GavilanJ . Idiopathic facial paralysis: a randomized, prospective, and controlled study using single‐dose prednisone versus acyclovir three times daily. Laryngoscope1998;108(4 Pt 1):573‐5. [PUBMED: 9546272] ">De Diego 1998</a>, <a href="http://archie.cochrane.org/sections/documents/view?version=z1405191846312167718941430126298%26format=REVMAN#STD-Hato-2007" target="_blank">Hato 2007</a>, <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a>, <a href="./references#CD001869-bbs2-0010" title="MinneropM , HerbstM , FimmersR , KaabarP , MatzB , KlockgetherT , et al. Bell's palsy: combined treatment of famciclovir and prednisone is superior to prednisone alone. Journal of Neurology2008;255(11):1726‐30. [PUBMED: 18769863] ">Minnerop 2008</a>, <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>, <a href="./references#CD001869-bbs2-0006" title="KhajehA , FayyaziA , SoleimaniG , Miri‐AliabadG , Shaykh VeisiS , KhajehB . Comparison of the efficacy of combination therapy of prednisolone ‐ acyclovir with prednisolone alone in Bell’s palsy. Iranian Journal of Child Neurology2015;9(2):17‐20. [PUBMED: 26221158] ">Khajeh 2015</a> and <a href="./references#CD001869-bbs2-0007" title="KhedrEM , BadryR , AliAM , Abo El‐FetohN , El‐HammadyDH , GhandourAM , et al. Steroid/antiviral treatment of Bell's palsy: double blind randomized clinical trial. Restorative Neurology and Neuroscience2016;34(6):897‐905. [PUBMED: 27689547] ">Khedr 2016</a> had methodological weaknesses, either in baseline group assessment or in completeness of follow‐up, and adequacy of blinding. Any of these factors could result in bias and introduce inaccuracy. Sensitivity analysis of trials not meeting current best standards (that is, high or unclear risk of bias) changed the findings from a large effect into little or no effect, especially in the primary outcome of our main analysis. We concluded that it was the studies at higher risk of bias that suggested benefit from the combination treatment. Our sensitivity analysis of trials with a six‐month endpoint corresponded with this finding and also showed a change in the result compared to the whole group analysis. </p> <p>Subgroup analyses on the whole data set revealed some differences between the different antivirals used. We showed a benefit for the combination treatment with aciclovir and famciclovir but not for valaciclovir. This appears to be a subgroup effect but this can also be explained by the heterogeneity of the trials. The statistical test for subgroup differences did not identify a significant difference. An additional analysis among participants with severe Bell's palsy, showed little or no effect of the combination treatment. Taking both into account, subgroup analyses and the analysis in people with severe Bell's palsy were helpful in explaining the heterogeneity of the overall analysis. </p> <p>From the data available for analysis of motor synkinesis or crocodile tears at the end of the study, the results favoured antiviral treatment in combination with corticosteroids compared to corticosteroid treatment alone or in combination with placebo, and also corticosteroid treatment alone or in combination with placebo compared to antiviral treatment alone or in combination with placebo (<a href="./references#CD001869-fig-0011" title="">Analysis 1.5</a>; <a href="./references#CD001869-fig-0016" title="">Analysis 2.3</a>). In the analysis of the whole data set (3 studies with a total of 941 participants), the degree of clinical heterogeneity (different clinical assessment scales used) and methodological heterogeneity (different treatment regimens and follow‐up plans) limited interpretation of the data. There was no clear difference between groups based on data from trials at a lower risk of bias, but the data were imprecise. </p> <p>Adverse event data were available in four studies, giving comparison data for 1592 participants, but the certainty of evidence was very low; the CIs in the analyses were wide and encompassed the possibility of an effect in either direction (<a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a>; <a href="./references#CD001869-bbs2-0004" title="HatoN , YamadaH , KohnoH , MatsumotoS , HondaN , GyoK , et al. Valacyclovir and prednisolone treatment for Bell's palsy: a multicenter, randomized, placebo‐controlled study. Otology and Neurotology2007;28(3):408‐13. [PUBMED: 17414047] ">Hato 2007</a>; <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>; <a href="./references#CD001869-bbs2-0011" title="ShahidullahM , HaqueA , IslamMR , RizviAN , SultanaN , MiaBA , et al. Comparative study between combination of famciclovir and prednisolone with prednisolone alone in acute Bell's palsy. Mymensingh Medical Journal: MMJ2011;20(4):605‐13. [CRS: 8300125000010514; EMBASE: 22081178; CN‐00857180; PUBMED: 22081178] ">Shahidullah 2011</a>). </p> <p>It was unclear whether time to treatment influenced recovery. Neither <a href="./references#CD001869-bbs2-0005" title="KawaguchiK , InamuraH , AbeY , KoshuH , TakashitaE , MurakiY , et al. Reactivation of herpes simplex virus type 1 and varicella‐zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope2007;117(1):147‐56. [PUBMED: 17202945] ">Kawaguchi 2007</a> nor <a href="./references#CD001869-bbs2-0014" title="YeoSG , LeeYC , ParkDC , ChaCI . Acyclovir plus steroid versus steroid alone in the treatment of Bell's palsy. American Journal of Otolaryngologyy2008;29(3):163‐6. [PUBMED: 18439948] ">Yeo 2008</a> found an association between time to treatment and final recovery status, but most of the trials did not provide data on this outcome. </p> <p>The review included studies conducted in Asia, North and Middle America, and Europe. It is possible that genetic differences in drug metabolism or response or even different aetiological processes may account for some of the observed variation in response. </p> <p>The primary outcome result raises another important consideration, namely health economic issues: a 10‐day course of aciclovir 400 mg five times per day costs GBP 2.04 (USD 2.69, EUR 2.29). The cost of valaciclovir is similar: 1000 mg three times per day for seven days costs GBP 10.12 (USD 12.97, EUR 11.38); 2 g once daily for seven days costs GBP 6.75 (USD 8.90, EUR 7.59), or 1000 mg once daily for 5 days costs GBP 2.41 (USD 3.18, EUR 2.71). Famciclovir 250 mg three times per day for seven days and 250 mg three times per day for five days is significantly more expensive and likely to cost the same at GBP 155.32 (USD 204.90, EUR 174.69). A 10‐day course of prednisolone (2 25 mg tablets daily) costs GBP 26.79 (USD 35.34, EUR 30.13), much less than for the antivirals. These cost data are specific to the UK market (<a href="./references#CD001869-bbs2-0063" title="National Health Service. The Surrey Downs Clinical Commisioning Group. www.surreydownsccg.nhs.uk2018. ">NHS Surrey Downs 2018</a>), and costs vary significantly in other countries (<a href="./references#CD001869-bbs2-0050" title="HernándezRA , SullivanF , DonnanP , SwanI , ValeL , BELLS Trial Group. Economic evaluation of early administration of prednisolone and/or aciclovir for the treatment of Bell's palsy. Family Practice2009;26(2):137‐44. [PUBMED: 19244470] ">Hernández 2008</a>). </p> <section id="CD001869-sec-0107"> <h4 class="title">Certainty of the evidence</h4> <p>The certainty of evidence in the current review does not allow robust conclusions regarding incomplete recovery for the comparison of antiviral treatment in combination with corticosteroids versus corticosteroid treatment alone or in combination with placebo (<a href="./full#CD001869-tbl-0001">summary of findings Table for the main comparison</a>). We downgraded the certainty of evidence for the main comparison to low since the risk ratio (RR) had a wide CI that included the possibility of very little effect (imprecision) and for inconsistency of the results. This analysis was performed after removal of studies at high or unclear risk of bias and did not confirm the previously demonstrated effect <a href="./full#CD001869-tbl-0001">summary of findings Table for the main comparison</a>. Some studies showed a benefit and others a detrimental effect of AS in participants with Bell's palsy. The funnel plot shows asymmetry of the distribution of the studies, indicating the possibility of publication bias and small‐study effects (<a href="#CD001869-fig-0006">Figure 6</a>). </p> <p>The body of evidence identified for motor synkinesis and crocodile tears was small because only two trials provided data and one of them had a small sample size. </p> <p>Very low‐certainty evidence showed no differences in the occurrence of adverse events. We downgraded the body of evidence due to publication bias, for imprecision, as the CIs were wide and encompassed the possibility of an effect in either direction, and because the proportion of participants lost to follow‐up was large in some of the included trials. </p> </section> </section> <section id="CD001869-sec-0108"> <h3 class="title" id="CD001869-sec-0108">Potential biases in the review process</h3> <p>To help ensure that decisions about which studies to include in this review were reproducible, two review authors repeated the review process. Regarding application of the eligibility criteria and assessing the relevance of studies, review authors were aware of the names of the study authors, institutions, journal of publication, and results. FS and FD were authors of the <a href="./references#CD001869-bbs2-0012" title="SullivanFM , SwanIR , DonnanPT , MorrisonJM , SmithBH , McKinstryB , et al. Early treatment with prednisolone or acyclovir in Bell's palsy. New England Journal of Medicine2007;357(16):1598‐607. [PUBMED: 17942873] ">Sullivan 2007</a> study. </p> <p>According to previous practice in this review, we excluded several studies and a published abstract for different reasons (<a href="#CD001869-sec-0073">Excluded studies</a>). As a result, there could be some risk of publication and selective reporting bias due to data from some studies being unavailable. </p> <p>At this update our main analyses excluded studies at high or unclear risk of bias in at least five domains. We listed this sensitivity analysis in the methods in a previous version of this review, but did not previously present it as the primary analysis. Even this restricted set of data included a trial at high risk of bias in two domains with a large effect size, which if excluded from the analysis would move the results of the efficacy analyses for antiviral treatment in combination with corticosteroids versus corticosteroid treatment alone or in combination with placebo closer towards the null (<a href="./references#CD001869-bbs2-0001" title="AdourKK , RuboyianesJM , VonDoerstenPG , BylFM , TrentCS , QuesenberryCPJr , et al. Bell's palsy treatment with acyclovir and prednisone compared with prednisone alone: a double‐blind, randomized, controlled trial. Annals of Otology, Rhinology and Laryngology1996;105(5):371‐8. [PUBMED: 8651631] ">Adour 1996</a>). The results are highly sensitive to study inclusion and risk of bias decisions, and true effects may be substantially different from the estimates in the review. We used the Cochrane 'Risk of bias' tool as currently implemented to assess bias in studies (<a href="./references#CD001869-bbs2-0051" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>), and checked and corrected previous judgements as appropriate. It is probable that implementation of the new 'Risk of bias' tool will again change estimates of effect (<a href="./references#CD001869-bbs2-0052" title="HigginsJP , SavovićJ , PageMJ , SterneJA , on behalf of the ROB2 Development Group. Revised Cochrane risk of bias tool for randomized trials (RoB 2). Available from sites.google.com/site/riskofbiastool/welcome/rob‐2‐0‐tool/current‐version‐of‐rob‐2 9 July 2019. ">Higgins 2019</a>). Future updates will restrict the main analyses to studies at a low overall risk of bias based on judgements in the new tool. </p> <p>On the advice of the Cochrane Neuromuscular Statistical Editor, we did not also perform a prespecified sensitivity analysis, excluding studies with fewer than 200 participants, which had also been described in the methods of a previous version of the review, as this was considered too arbitrary a restriction. </p> </section> <section id="CD001869-sec-0109"> <h3 class="title" id="CD001869-sec-0109">Agreements and disagreements with other studies or reviews</h3> <p>We found two systematic reviews, three meta‐analyses and a network meta‐analysis comparing corticosteroids and antivirals for the treatment of Bell's palsy (<a href="./references#CD001869-bbs2-0042" title="deAlmeidaJR , Al KhaboriM , GuyattGH , WitterickIJ , LinVY , NedzelskiJM , et al. Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta‐analysis. JAMA2009;302(9):985‐93. [PUBMED: 19724046] ">de Almeida 2009</a>; <a href="./references#CD001869-bbs2-0047" title="GoudakosJK , MarkouKD . Corticosteroids versus corticosteroids plus antiviral agents in the treatment of Bell Palsy: a systematic review and meta‐analysis. Archives of Otolaryngology ‐ Head &amp; Neck Surgery2009;135(6):558‐64. [PUBMED: 19528403] ">Goudakos 2009</a>; <a href="./references#CD001869-bbs2-0069" title="QuantEC , JesteSS , MuniRH , CapeAV , BhussarMK , PelegAY . The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta‐analysis. BMJ2009;339:b3354. [PUBMED: 19736282] ">Quant 2009</a>; <a href="./references#CD001869-bbs2-0065" title="NumthavajP , ThakkinstianA , DejthevapornC , AttiaJ . Corticosteroid and antiviral therapy for Bell's palsy: a network meta‐analysis. BMC Neurology2011;11(1):1‐10. [DOI: 10.1186/1471‐2377‐11‐1; PUBMED: 21208452] ">Numthavaj 2011</a>; <a href="./references#CD001869-bbs2-0043" title="DongY , ZhuY , MaC , ZhaoH . Steroid‐antivirals treatment versus steroids alone for the treatment of Bell's palsy: a meta‐analysis. International Journal of Clinical and Experimental Medicine2015;8(1):413‐21. [PUBMED: 25785012] ">Dong 2015</a>; <a href="./references#CD001869-bbs2-0046" title="FuX , TangL , WangC , LiM , WuH , LiJ , et al. A network meta‐analysis to compare the efficacy of steroid and antiviral medications for facial paralysis from Bell's palsy. Pain Physician2018;21(6):559‐69. [PUBMED: 30508985] ">Fu 2018</a>). De Almeida and colleagues compared any corticosteroid treatment with antivirals and included 18 trials in the meta‐analysis. Some of the trials did not meet the inclusion criteria for this review (i.e. for follow‐up duration of at least 3 months). De Almeida reported a benefit from corticosteroids for people with Bell's palsy and the probability of additional benefit when corticosteroids were combined with antivirals. A systematic review and meta‐analysis by Goudakos and colleagues compared corticosteroids with corticosteroids plus antivirals for the treatment of Bell's palsy. This review included only four trials and omitted other important studies, for example <a href="./references#CD001869-bbs2-0003" title="EngströmM , BergT , Stjernquist‐DesatnikA , AxelssonS , PitkärantaA , HultkrantzM , et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double blind, placebo controlled, multicentre trial. Lancet Neurology2008;7(11):993‐1000. [DOI: 10.1016/51474‐4422(08)70221‐7; PUBMED: 18849193] ">Engström 2008</a>, which is the largest trial conducted on this topic. Goudakos did not find an additional benefit from combining corticosteroids with antivirals. The meta‐analyses by Numthavaj and colleagues and Quant and colleagues included six trials for analysis, with a great overlap (<a href="./references#CD001869-bbs2-0069" title="QuantEC , JesteSS , MuniRH , CapeAV , BhussarMK , PelegAY . The benefits of steroids versus steroids plus antivirals for treatment of Bell's palsy: a meta‐analysis. BMJ2009;339:b3354. [PUBMED: 19736282] ">Quant 2009</a>; <a href="./references#CD001869-bbs2-0065" title="NumthavajP , ThakkinstianA , DejthevapornC , AttiaJ . Corticosteroid and antiviral therapy for Bell's palsy: a network meta‐analysis. BMC Neurology2011;11(1):1‐10. [DOI: 10.1186/1471‐2377‐11‐1; PUBMED: 21208452] ">Numthavaj 2011</a>). In both papers the authors reported higher rates of recovery when corticosteroids were combined with antivirals compared to corticosteroids alone, but the difference was small. Also Dong and colleagues recommended the combination treatment of corticosteroids and antivirals, based on the results of a meta‐analysis with eight trials (<a href="./references#CD001869-bbs2-0043" title="DongY , ZhuY , MaC , ZhaoH . Steroid‐antivirals treatment versus steroids alone for the treatment of Bell's palsy: a meta‐analysis. International Journal of Clinical and Experimental Medicine2015;8(1):413‐21. [PUBMED: 25785012] ">Dong 2015</a>). Fu and colleagues conducted a network meta‐analysis and included data of 4623 participants from 23 studies. The analysis comprised a large number of studies and included also data of a withdrawn trial <a href="./references#CD001869-bbs2-0015" title="AbdelghanyAM , KamelSB . Retracted: the effect of prednisolone and/or acyclovir in relation to severity of Bell's palsy at presentation. Egyptian Journal of Ear, Nose, Throat and Allied Sciences2013;14(3):155‐9. [DOI: https://doi.org/10.1016/j.ejenta.2013.04.003] AbdelghanyAM , KamelSB . Retraction notice to ‘‘The effect of prednisolone and/or acyclovir in relation to severity of Bell’s palsy at presentation” [Egypt. J. Ear NoseThroat Allied Sci 14(3) (2013) 155–9]. Egyptian Journal of Ear, Nose and Throat2017;18(3):329. [DOI: org/10.1016/j.ejenta.2013.04.003] ">Abdelghany 2013</a>. The authors concluded that the effect of the combined treatment of antivirals and corticosteroids was significantly better than antiviral or corticosteroid therapy alone with regard to overall recovery in people with Bell's palsy (<a href="./references#CD001869-bbs2-0046" title="FuX , TangL , WangC , LiM , WuH , LiJ , et al. A network meta‐analysis to compare the efficacy of steroid and antiviral medications for facial paralysis from Bell's palsy. Pain Physician2018;21(6):559‐69. [PUBMED: 30508985] ">Fu 2018</a>). However, none of the meta‐analyses reported data from studies with a low risk of bias separately, as the current meta‐analysis does. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001869-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001869-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="A summary of review authors' 'Risk of bias' assessments for included studies. Red = high risk of bias; yellow = unclear risk of bias; green = low risk of bias." data-id="CD001869-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>A summary of review authors' 'Risk of bias' assessments for included studies. Red = high risk of bias; yellow = unclear risk of bias; green = low risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): sensitivity analysis based on risk of bias (excluding studies at high or unclear risk of bias in fewer than five domains), outcome: 1.1 Incomplete recovery at end of study." data-id="CD001869-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): sensitivity analysis based on risk of bias (excluding studies at high or unclear risk of bias in fewer than five domains), outcome: 1.1 Incomplete recovery at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data set)." data-id="CD001869-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data set). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 3 Antivirals plus corticosteroids versus placebo, outcome: 3.1 Incomplete recovery at end of study." data-id="CD001869-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 3 Antivirals plus corticosteroids versus placebo, outcome: 3.1 Incomplete recovery at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data set)." data-id="CD001869-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, outcome: 1.2 Incomplete recovery at end of study (full data set). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 1 Incomplete recovery at end of study (trials at lower risk of bias)." data-id="CD001869-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 1 Incomplete recovery at end of study (trials at lower risk of bias). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-001-02.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 2 Incomplete recovery at end of study (full data set)." data-id="CD001869-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 2 Incomplete recovery at end of study (full data set). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 3 Incomplete recovery at end of study in severe cases: data set limited to trials at lower risk of bias." data-id="CD001869-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 3 Incomplete recovery at end of study in severe cases: data set limited to trials at lower risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 4 Incomplete recovery at end of study in severe cases: full data set." data-id="CD001869-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 4 Incomplete recovery at end of study in severe cases: full data set. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 5 Motor synkinesis or crocodile tears." data-id="CD001869-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 5 Motor synkinesis or crocodile tears. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 6 Adverse events (trials at lower risk of bias)." data-id="CD001869-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 6 Adverse events (trials at lower risk of bias). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 7 Adverse events (full data set)." data-id="CD001869-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias, Outcome 7 Adverse events (full data set). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 1 Incomplete recovery at end of study: trials at lower risk of bias." data-id="CD001869-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 1 Incomplete recovery at end of study: trials at lower risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 2 Incomplete recovery at end of study: full data set." data-id="CD001869-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 2 Incomplete recovery at end of study: full data set. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 3 Motor synkinesis and crocodile tears: trials at lower risk of bias." data-id="CD001869-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 3 Motor synkinesis and crocodile tears: trials at lower risk of bias. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 4 Motor synkinesis and crocodile tears: full data set." data-id="CD001869-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 4 Motor synkinesis and crocodile tears: full data set. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 5 Adverse events." data-id="CD001869-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias, Outcome 5 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-003-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antivirals plus corticosteroids versus placebo (AS versus OO), Outcome 1 Incomplete recovery at end of study." data-id="CD001869-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Antivirals plus corticosteroids versus placebo (AS versus OO), Outcome 1 Incomplete recovery at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antivirals plus corticosteroids versus placebo (AS versus OO), Outcome 2 Motor synkinesis or crocodile tears." data-id="CD001869-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Antivirals plus corticosteroids versus placebo (AS versus OO), Outcome 2 Motor synkinesis or crocodile tears. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Antivirals plus corticosteroids versus placebo (AS versus OO), Outcome 3 Adverse events." data-id="CD001869-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Antivirals plus corticosteroids versus placebo (AS versus OO), Outcome 3 Adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antivirals versus placebo (AO versus OO), Outcome 1 Incomplete recovery at end of study." data-id="CD001869-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Antivirals versus placebo (AO versus OO), Outcome 1 Incomplete recovery at end of study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antivirals versus placebo (AO versus OO), Outcome 2 Motor synkinesis or crocodile tears." data-id="CD001869-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Antivirals versus placebo (AO versus OO), Outcome 2 Motor synkinesis or crocodile tears. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001869-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/urn:x-wiley:14651858:media:CD001869:CD001869-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_t/tCD001869-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Antivirals versus placebo (AO versus OO), Outcome 3 Adverse events." data-id="CD001869-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Antivirals versus placebo (AO versus OO), Outcome 3 Adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/media/CDSR/CD001869/image_n/nCD001869-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001869-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment (AS versus OS) for Bell's palsy (idiopathic facial paralysis)</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment (AS versus OS) for Bell's palsy (idiopathic facial paralysis)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> Bell's palsy (idiopathic facial paralysis)<br/> <b>Setting:</b> primary, secondary and tertiary care<br/> <b>Intervention:</b> antivirals plus corticosteroids (AS)<br/> <b>Comparison:</b> corticosteroids plus placebo or no treatment (OS) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>What happens</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corticosteroids plus placebo or no treatment (OS)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Antivirals plus corticosteroids (AS)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Difference with AS</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Incomplete recovery at end of study<br/> № of participants: 766<br/> (3 RCTs) </p> <p>Follow‐up: 3 to 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.81<br/> (0.38 to 1.74) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> Low<sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>There may be little or no difference between AS and OS in the proportion of participants with incomplete recovery at the end of the studies. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>172 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140 per 1000 (65 to 300)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 fewer per 1000<br/> (107 fewer to 128 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Motor synkinesis or crocodile tears<br/> № of participants: 469<br/> (2 RCTs) </p> <p>Follow‐up: 3 to 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR 0.56<br/> (0.36 to 0.87) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/> Moderate<sup>c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>AS probably reduces the proportion of participants with motor synkinesis or crocodile tears at 3 to 12 months compared to OS. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>194 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109 per 1000 (70 to 169)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85 fewer per 1000 (124 fewer to 25 fewer per 1000)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Adverse events<br/> № of participants: 656<br/> (2 RCTs) </p> <p>Follow‐up: 3 to 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>RR<br/> 1.17 (0.81 to 1.68) </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>d,e</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>It is uncertain whether the number of people who experience adverse events is different with AS than OS. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160 per 1000 (110 to 229)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 more per 1000 (26 fewer to 93 more)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>AS</b> : antivirals plus corticosteroids; <b>CI:</b> confidence interval; <b>OS</b> : corticosteroids plus placebo or no treatment; <b>RR:</b> risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High certainty</b> : we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty</b> : we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty</b> : our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty</b>: we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>We downgraded the certainty of evidence once due to differing results of the included studies (inconsistency). As our primary analysis we reported the results of a sensitivity analysis excluding 10 of 13 trials which were at high or unclear risk of bias in several domains. The effect estimate from the full data set was RR 0.54, 95% CI 0.38 to 0.77; 13 trials, N = 1729 , but there were very serious study limitations in the full data set, in addition to heterogeneity.<br/> <sup>b</sup>We downgraded the certainty of the body of evidence once because the RR had wide CIs that included the possibility of a very little effect and a large effect (imprecision).<br/> <sup>c</sup>We downgraded the certainty of evidence for this outcome for publication bias, as only two studies in this comparison reported this outcome.<br/> <sup>d</sup>We downgraded the certainty of the body of evidence for this outcome once for publication bias as only 4 of the 13 studies reported adverse events.<br/> <sup>e</sup>We downgraded the certainty of the body of evidence twice for imprecision as the CIs were wide and encompassed the possibility of an effect in either direction. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antivirals plus corticosteroids compared to corticosteroids plus placebo or no treatment (AS versus OS) for Bell's palsy (idiopathic facial paralysis)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001869-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">House‐Brackmann Scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Grade</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Description</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild dysfunction; slight weakness noticeable only on close inspection; may have slight synkinesis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderate dysfunction; obvious but not disfiguring difference between the 2 sides; noticeable but not severe synkinesis </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moderately severe dysfunction; obvious weakness or disfiguring asymmetry, or both</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Only barely perceptible motion</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No movement</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="2"> <div class="table-footnote"> <p><a href="./references#CD001869-bbs2-0053" title="HouseJW . Facial nerve grading systems. Laryngoscope1983;93:1056‐69. ">House 1983</a>; <a href="./references#CD001869-bbs2-0054" title="HouseJW , BrackmannDE . Facial nerve grading system. Otolarnygology ‐ Head &amp; Neck Surgery1985;93(2):146‐7. [PUBMED: 3921901] ">House 1985</a> </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">House‐Brackmann Scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001869-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sunnybrook Scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Facial grading system</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Resting symmetry</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Symmetry of voluntary movement</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Synkinesis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Compared to normal side</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Degree of muscle excursion compared to normal side</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Degree of involuntary muscle contraction associated with each expression</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Eye</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p><b>Standard expressions</b> </p> <p>Forehead wrinkle</p> <p>Gentle eye closure</p> <p>Open mouth smile</p> <p>Snarl</p> <p>Lip pucker</p> <p>Score each out of 5, where 5 is normal and 1 is gross asymmetry/no movement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="14" valign="top"> <p><b>Standard expressions</b> </p> <p>Forehead wrinkle</p> <p>Gentle eye closure</p> <p>Open mouth smile</p> <p>Snarl</p> <p>Lip pucker</p> <p>Score each facial movement listed under standard expressions on a scale 0 to 3, where 0 is no asymmetry and 3 is severe asymmetry </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal = 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Narrow = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wide =1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eyelid surgery = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Cheek</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal = 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Absent = 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Less pronounced = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>More pronounced =1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Mouth</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal = 0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corner drooped =1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Corner pulled up/out = 1</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TOTAL</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resting symmetry score x 5</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Voluntary movement score</b> </p> <p><b>Total x 4</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Synkinesis score</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Voluntary movement score ‐ resting symmetry score ‐ synkinesis score = composite Score</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Weighted regional evaluation using five separate expressions. Composite score from 0 (total paralysis) to 100 (normal function) (<a href="./references#CD001869-bbs2-0071" title="RossBG , FradetG , NedzelskiJM . Development of a sensitive clinical facial grading system. Otolargynology ‐ Head and Neck Surgery1996;114(3):380‐6. [PUBMED: 8649870] ">Ross 1996</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Sunnybrook Scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001869-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Yanagihara Scale</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Mode</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Degree of paralysis</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>4</b> </p> <p>normal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>3</b> </p> <p>slight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>2</b> </p> <p>moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>1</b> </p> <p>severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>0</b> </p> <p>total</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>At rest</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wrinkle forehead</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blink</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Normal closure of eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Forced closure of eye</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Closure of eye on involved side</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Wrinkle nose</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whistle</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Grin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depress lower lip/ blow out cheek</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>10 separate categories of function, each scored 0 (total paralysis) to 4 (normal), then summed, giving a total score from 0 (total paralysis) to 40 (normal function) (<a href="./references#CD001869-bbs2-0074" title="YanagiharaN . Grading of facial palsy. Third international symposium on facial nerve surgery; 1976 Aug 9‐12; Zurich. Birmingham (AL): Aesculapius, 1977:533‐5. ">Yanagihara 1977</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Yanagihara Scale</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/full#CD001869-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001869-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incomplete recovery at end of study (trials at lower risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>766</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.38, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Aciclovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>350</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.14, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Valaciclovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.60, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incomplete recovery at end of study (full data set) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1729</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.38, 0.77]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Aciclovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>580</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.22, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Famciclovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>321</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.48 [0.22, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Valaciclovir</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>828</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.57, 1.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Incomplete recovery at end of study in severe cases: data set limited to trials at lower risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>98</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.57, 1.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Incomplete recovery at end of study in severe cases: full data set <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.41, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Motor synkinesis or crocodile tears <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>469</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.36, 0.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Adverse events (trials at lower risk of bias) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.17 [0.81, 1.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Adverse events (full data set) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>945</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.83, 1.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment (AS versus OS): trials at lower risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001869-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incomplete recovery at end of study: trials at lower risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>667</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.69 [0.73, 10.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incomplete recovery at end of study: full data set <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.82 [1.09, 7.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Motor synkinesis and crocodile tears: trials at lower risk of bias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.15, 2.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Motor synkinesis and crocodile tears: full data set <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.52 [1.08, 2.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.57, 1.28]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Antivirals versus corticosteroids (AO versus OS): trials at lower risk of bias</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001869-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antivirals plus corticosteroids versus placebo (AS versus OO)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incomplete recovery at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.42, 0.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Motor synkinesis or crocodile tears <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>372</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.23, 0.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>649</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.14 [0.79, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Antivirals plus corticosteroids versus placebo (AS versus OO)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001869-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antivirals versus placebo (AO versus OO)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incomplete recovery at end of study <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>658</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.87, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Motor synkinesis or crocodile tears <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>373</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.75, 1.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>651</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.56, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Antivirals versus placebo (AO versus OO)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001869.pub9/references#CD001869-tbl-0008">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001869.pub9&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001869-note-0006">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001869-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001869-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD001869-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD001869-note-0014">Magyar</a> </li> <li class="section-language"> <a class="" href="ms#CD001869-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD001869-note-0005">Polski</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001869-note-0001">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD001869-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001869\x2epub9"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001869\x2epub9"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001869\x2epub9"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001869\x2epub9\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001869\x2epub9"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=STpJR8yz&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001869.pub9&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001869.pub9';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001869.pub9/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001869.pub9/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001869.pub9%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714657128"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001869.pub9/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714657132"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001869.pub9/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d7407f8b9937f',t:'MTc0MDcxNDY1Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 